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Senile dementia and Alzheimer's disease are the
commonest forms of dementia occurring in the senium and
presenium respectively. They have devastating effects
on sufferers and their families, and as the proportion
of the elderly population increases, serious economic
consequences for the health and social services of the
country.
The relationship of Alzheimer's disease to senile
dementia has been debated since Alzheimer first
described the disease in 1907 (1-3). Alzheimer thought
that the disease he described represented a premature
form of senile dementia but Kraepelin considered that it
was a disease sui generis. However most clinical,
neuropathological and genetic studies support the theory
that they constitute a single disease entity rather than
representing two distinct diseases.
Recent studies (1,3,4) have found that the clinical
features are very similar in both disorders. Tradition¬
ally the presence of parietal lobe features such as
apraxia, agnosia and aphasia, have been considered to be
characteristic of Alzheimer's disease, and rare in
senile dementia, but recent studies cast doubt on this
teaching. Lauter and Meyer (3) found a high incidence
of parietal lobe features in senile dements, and
McDonald (5) also confirmed their presence in senile
dementia, although he found that they tended to occur in
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the younger patients, and perhaps conferred a poorer
prognosis.
Sourander and Sjogren (6) argue that Alzheimer's
disease and senile dementia are separate disorders
because they are distinguishable in terms of intensity
of neuropathological changes. However the pathological
features of both disorders are essentially identical
(1,3,4) making their histological differentiation
impossible in many cases without a clinical history.
Support for a genetic distinction between
Alzheimer's disease and senile dementia rests on the
findings of Larsson, Sjogren and Jacobsen (105), who
reported no cases of Alzheimer's disease in over 2000
first degree relatives of senile dements. However a
careful reading of their results reveals that 10 second¬
ary cases of dementia occurred in the presenile age
group. The results of other genetic studies (shortly to
be reviewed), and the report by Stam and Op den Velde
(7,8) of an association of the haptoglobin Hp1 gene with
Alzheimer's disease and senile dementia, do not support
a genetic distinction.
Therefore it is difficult not to accept Newton's
conclusion (1) that there are no clear grounds for
distinguishing between Alzheimer's disease and senile
dementia except by the arbitrary limits of age, and
perhaps rate of progression and severity of neuropath¬
ological changes, and that both diseases are examples
of the same disorder. As a recognition of this unitary
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concept, the terms presenile dementia of the Alzheimer
type (PDAT) and senile dementia of the Alzheimer type
(SDAT) have been proposed (9), and will be used in the
remainder of this thesis. When the term Alzheimer's
disease (AD) is used, it will refer to PDAT and SDAT, and
not specifically to the form of the disease occurring
before the age of 65.
For various reasons there has been little basic
research into AD, and its aetiology is unknown. However
the increased risk of developing AD in the close
relatives of a minority of patients suffering from this
disorder, implies that genetic factors may be of
aetiological importance in some cases. AD also has
features which suggest that immunological factors may be
involved in its pathogenesis, although few studies have
attempted to identify their nature.
It has recently been recognised that a number of
slowly progressive diseases of the central nervous
system, previously thought to be heredo-degenerative
disorders, are caused by slow virus infections. As yet,
there have been few studies which have examined the
possible involvement of viruses in the aetiology of AD
although this disease has some histological and biochem¬
ical features which are compatible with a viral
aetiology.
A number of human diseases, some of which are
thought to be immunologically mediated, are associated
with particular HLA antigens, ABO and Rhesus blood
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groups, and such studies have helped to clarify some of
the genetic and immunological factors operating in these
disorders.
Human cytomegalovirus (CMV) is a common virus which
may rarely cause neurological disease associated with
primary infection. Following primary infection the virus
becomes latent in tissues or cells which are as yet un¬
identified. Reactivation of CMV is a well recognised
phenomenon and it is conceivable that such reactivation
may cause neurological disease. The possible involvement
of the CMV in AD is suggested by a Swedish study (366)
which found that demented patients had higher antibody
titres to CMV than functionally-ill psychiatric patients.
The principal aims of the study were:
1) To identify possible genetic and immunological
factors in AD, by studying ABO and Rhesus blood
groups, and HLA antigens, in patients suffering from
this disorder.
2) To clarify the nosological relationship
between PDAT and SDAT using these genetic markers,
and by family studies.
3) To determine if any HLA antigen, found to be
significantly associated with AD, influences the
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clinical features of the disorder.





1) Some psychiatric, pathological and aetiological
aspects of PDAT and SDAT, with particular reference
to genetic, immunological and viral studies.
2) The relationship of AD to normal ageing, and
the age-related changes in the immune system.
3) Slow virus infections of the central nervous
system, with particular reference to subacute
sclerosing panencephalitis, progressive multifocal
leukoencephalopathy, kuru and Creutzfeldt-Jakob
disea se.




A study of 37 inpatients suffering from PDAT and
87 inpatients suffering from SDAT is described. The case
histories of a female patient suffering from PDAT, with
an identical twin discordant for the disease, and a 15
year old girl with Creutzfeldt-Jakob disease, are also
de scribed.
The frequencies of the ABO and Rhesus blood groups,
and the principle HLA-A and -B antigens were determined
in the patients, and compared with the respective
frequencies in a group of hospital staff and blood donors
drawn from similar geographical catchment areas as the
patients. Serum antibody titres to CMV were also
determined in the patients and a similarly aged control
group of 39 non-demented psychiatric inpatients for
comparison.
The next of kin of 34 of the study patients were
interviewed, and the cases of AD occurring in first
degree relatives identified.
On completion of the study, the data was drawn
together and analyzed.
The Main Findings of the Study:
1) The ABO blood group frequencies of the
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patients did not differ significantly from two
control groups of Leeds blood donors.
2) SDAT patients showed a slight but significant
increase in the frequency of the Rhesus negative
blood group compared with controls (relative risk
1.8, P < 0.05).
When this result is combined with data from similar
reported studies using Woolf*s method of statistical
analysis (521,522), the association of SDAT with the
Rhesus negative blood group is highly significant
( P = 0o0002 )«,
3) Patients suffering from PDAT and SDAT showed a
significant increase of HLA-B15 ( PDAT : relative
risk 3.0, P<0.005 ; SDAT : relative risk 2.3,
P< 0.005 ).
When these results are combined with data from
similar reported HLA studies of AD using Woolf's
formula, the association of AD with HLA-B15 remains
statistically significant ( P = 0.0015 ).
4) The frequency of HLA-A2 was non-significantly
increased in the PDAT and SDAT patients. However
the combination of this result with data from other
studies using Woolf's method, shows a statistically
significant association of AD with HLA-A2 ( P =
0„04)o
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5) As in other similar studies, this study found
a small non-significant increase in the frequency of
HLA-B40 in patients with AD.
6) There were no significant differences in the
frequency of HLA-B15 in male and female patients.
7) No significant differences were found in mean
age at onset, or duration of disease, when HLA-B15
positive and negative patients were compared.
8) No significant difference was observed in the
frequency of AD among first degree relatives of HLA
-B15 positive and HLA-B15 negative patients matched
for sex and age at onset of disease.
9) Most of the secondary cases of AD were dead,
and only two could be personally examined. The two
secondary cases of AD were relatives of HLA-B15
positive patients, and both were also HLA-B15
positive. Cases of PDAT and SDAT were found to
occur within the same families.
10) Patients and controls did not differ
significantly in the prevalence of serum antibody
titres, or serum geometric mean titres to CMV.
11) HLA-B15 positive patients showed a
10
significantly higher serum geometric mean titre to
CMV compared with HLA-B15 negative patients.
12) A histological diagnosis was obtained in 18
patients. AD was confirmed in 15 patients, and mixed
AD - multi-infarct dementia in 2 further cases.
Multi-infarct dementia was diagnosed in another
patient, and he was excluded from the study.
13) Biopsy specimens of the brain, liver and kidney
from 8 patients were inoculated into human embryonic
lung fibroblasts but failed to induce the cytopathic
effects characteristic of CMV.
The results of the study are discussed in relation
to the findings of other studies, and various mechanisms
are proposed by which the above immunological and viral
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CLINICAL FEATURES OF PRESENILE DEMENTIA OF THE ALZHEIMER
TYPE (PDAT):
PDAT is characterized by a slowly progressive mental
deterioration with impairment of memory, disorientation,
and confusion, leading eventually to profound dementia,
starting before the age of 65 (6,10-12).
It is by far the most common of the presenile
dementias, and females are apparently more often affected
than males (13). Sjogren et al (14) reported a combined
N
morbidity risk of 0.1% for PDAT and Pick's disease, and
Terry (13) estimated a prevalence rate of 0.3% for PDAT.
The onset is insidious and usually starts between
the ages of 50 and 60 years. Three main stages are
typically described.
In the first stage, lasting 2-3 years, memory begins
to fail, and the patient becomes disorientated in time
and place. The ability to cope with everyday activities
is lost, and mood disturbances such as perplexity,
agitation or apathy may occur.
There is a progressive deterioration of intellect
and personality, and aphasia, apraxia, agnosia and
acalculia may be seen reflecting parietal lobe involve¬
ment by the disease process. Extrapyramidal disorders
can occur in the form of disturbance of posture, increase
in muscle tone, and other parkinsonian features as a
result of lesions in the basal ganglia and frontal lobes,
and the patient may become deluded and hallucinated.
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Finally the patient sinks into the bedridden
terminal stage of profound dementia, with total memory
loss, emaciation, double incontinence, limb contractures,
and frequently seizures. Death usually occurs from
bronchopneumonia within 5-10 years of the onset.
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CLINICAL FEATURES OF SENILE DEMENTIA OP THE ALZHEIMER
TYPE (SPAT):
Roth (15) defines SDAT as:
f,a condition with a history of gradual and continu¬
ally progressive failure in the common activities of
everyday life and a clinical picture dominated by failure
of memory and intellect and disorganization of a
personality, where these were not attributable to
specific causes such as infection, neoplasm, chronic
intoxication or cerebrovascular disease known to have
produced cerebral infarction. "
SDAT develops insidiously after the age of 64, and
occurs more commonly in women (16). Kay et al (17)
reported a prevalence rate of 4.2% for SDAT, and 3.9%
for multi-infarct dementia in the Newcastle region. They
also observed that in half the cases the severity of
mental deterioration was similar to that usually found in
demented hospital patients, and that over 80% of the
patients suffering from dementia were still living at
home. The results of other prevalence studies agree
broadly with the Newcastle findings (16-20). The
prevalence of SDAT rises steeply with age, and is about
eight times as common in the over 75's as those aged
between 65-75 years (21).
The typical signs and symptoms of the disease (15,
22, 23) are essentially identical to those of PDAT:
The first sign is usually impairment of memory for
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recent events. Further memory deterioration is
accompanied by disorientation and previous personality
traits may become exaggerated, sleep disturbance is
common, and acute confusional states may be seen super¬
imposed on the underlying dementia.
Once established, factors such as intercurrent
illness, drugs, medical procedures such as lumbar
puncture or pneumoencephalography, a sudden change in
environment, or the loss of a spouse, can adversely
affect the progress of the disease.
Agitation, depression and paranoid ideation are
common as intellect and personality continue to decline.
As the disease advances, there is typically disinhibition,
blunting of emotion, deterioration of personal habits,
loss of sphincter control, and the appearance of
repetitive futile behaviour such as rocking movements.
However McDonald (5) found evidence of clinical
heterogeneity, and was able to classify patients into
two groups on the basis of parietal lobe involvement.
Patients with preserved parietal lobe function were
significantly older and had a much better six-month
prognosis than those with deteriorated parietal lobe
function.
In the terminal stages of the disease, the patient
rapidly loses weight despite adequate food intake, and
usually dies within a few years from the onset due to an
intercurrent infection. At post-mortem the viscera and
body are often atrophied, possibly because of the involve-
20
ment of the hypothalamus, and its connections to the
limbic system, by the disease process (24).
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PATHOLOGICAL FEATURES OF PRESENILE AND SENILE DEMENTIA OF
THE ALZHEIMER TYPE:
Corsellis (25) states that PDAT cannot be disting¬
uished from SDAT on histological grounds, "all the
differences being of emphasis or of quantity rather than
intrinsic". Therefore the description of the neuropath-
ological features which follows applies both to PDAT and
SDAT, although they are said to be more severely
developed in the former.
There is usually generalized cortical atrophy, often
with emphasis on the frontal and temporal lobes, and the
ventricles are frequently enlarged (25,26).
Degeneration of neurons and loss of dendritic spines (27),
particularly in the outer three cortical layers are
extensive, and senile plaques, neurofibrillary tangles
and granulovacuolar degeneration are present throughout
the cortex, with emphasis on the hippocampal and
amygdaloid regions of the limbic area (28-36). The
marked degeneration in the limbic system is of
particular interest, as this area of the brain has been
shown to play an important role in emotion, behaviour,
memory and intellect.
The senile plaques (28,30-36) are roughly
spherical areas of disintegrating tissue ranging from
5/0. to 100 ju. in diameter, which are found scattered
throughout the cerebral cortex, and their origin is a
matter of considerable debate. Several types of plaque
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which differ in structure have been described (219). The
typical senile plaque consists of a central amyloid core,
surrounded by a ring of filamentous material containing
degenerative neuronal processes, post-synaptic boutons,
macrophages, microglia, reactive oligodendroglia,
degenerating mitochondria, and astrocytes.
The neurofibrillary tangles (29,30,32-36) found in
the cell bodies of neurons and their processes, are
composed of bundles of paired 10 nm helical filaments
(36-38).
Evidence suggests that the senile plaque amyloid
and the paired helical filaments contain protein with a
similar p-pleated sheet structure.
Granulovacuolar degeneration (35) - the formation
of membrane-bound vacuoles each containing a central
clump of finely granular material - are found mainly in
the hippocampal pyramidal cells. Affected neurons may
also show an accumulation of lipofuscin pigment (35).
Amyloid deposits (congophilic angiopathy) (39) are
also found in the cerebral arteries, and arterioles, the
adventitia of veins and venules, and the basement
membranes of capillaries.
The subcortical grey matter is much less severely
affected, and senile plaques are not found in the white
matter. However the latter may show axonal degeneration,
astrocytic hyperplasia, and fibrous gliosis.
24
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AETIOLOGY OF ALZHEIMER'S DISEASE;
The aetiology of AD is unclear. Human and animal
studies suggest that the cholinergic system of the brain
is important in memory function (40-42). The activity of
choline acetyltransferase, a key enzyme in the synthesis
of the neurotransmitter acetylcholine, is reduced in AD
brains (43-46). It has therefore been suggested that the
disease is associated with the failure of cholinergic
transmission, but attempts to increase the concentration
of brain acetylcholine by the administration of
precursors such as choline (47-52), lecithin (53-55) and
physostigmine (55,56) have led to equivocal results.
Recently a far wider disturbance of neurotransmitter
systems has been postulated, with the dopamine, gamma-
aminobutyric acid, and noradrenergic systems all
affected (57).
Neurofibrillary tangles of the paired helical type
have been found in the brains of patients suffering from a
variety of diseases (58,59), which suggests either that
they can be induced by a wide variety of pathological
agents, or are a non-specific reaction in chronically-
diseased brains. Neurofibrillary tangles have been
reported in viral diseases, in infections such as
tuberculosis, scarlet fever and dysentery, in the punch
drunk syndrome, and in other disorders in which
chromosomal abnormalities, inborn errors of metabolism,
and metal intoxications are implicated (59). Curiously
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patients with Down's syndrome who survive into middle age
are predisposed to the development of a presenile dementia
which is pathologically similar to AD (60-62).
The results of cytogenetic chromosomal studies of
peripheral lymphocytes in patients with AD have been
conflicting (63-70), and it is unclear if chromosomal
abnormalities during life play any aetiological role in the
disease. However the observation by Galloway and Buckton
(71) of a loss of chromosome 21 from cultured peripheral
blood cells in an ageing population, could be important if
viruses were implicated in AD. Whalley and Buckton (62)
have speculated that as chromosome 21 may be necessary for
human interferon to be effective, the loss of this
chromosome in sufficient numbers of small lymphocytes in
old people could result in defective interferon production,
and increased susceptibility to infection.
Aluminium can also induce neurofibrillary tangles in
experimental animals (73,74), although they differ
morphologically from the tangles found in AD. Crapper et
al (75) found raised brain aluminium levels in AD and
suggested that this metal might have a neurotoxic role in
the disease. This finding is of interest as some patients
undergoing chronic renal dialysis develop an encephalo¬
pathy which has been attributed to aluminium intoxication
(76,77), although neurofibrillary tangles are absent from
the brain. However McDermott et al (78,79) found no
differences in aluminium brain concentrations between
mentally normal patients and patients with AD, and
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suggested that high aluminium levels are related to age
rather than dementia. Further doubt on the aetiological
role of aluminium has been cast by Delaney (80) who
reported that spinal fluid levels of aluminium are low in
AD patients.
There is clear evidence that genetic factors are
implicated in both PDAT and SDAT. The age-related
changes in the immune system, and the immunological
abnormalities found in AD by some workers also suggests
that immune factors may be involved in the aetiology of
AD. The recognition of human slow virus infections of the
central nervous system, has also prompted speculation that
viruses might play an aetiological role in AD. The
evidence in support of a genetic, immunological and
viral aetiology will shortly be examined.
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THE RELATIONSHIP OF ALZHEIMER'S DISEASE TO NORMAL AGEING:
The relationship of AD to normal ageing is unclear.
Krai (81,82) has attempted to define two types of
senescent memory impairment. In the benign form, subjects
are able to recall the main features of a past experience,
although have difficulty in recalling specific names and
places. Both sexes are equally affected, and the subjects
retain insight into their forgetfulness, which deteriorates
only slowly. However in Krai's malignant form subjects are
unable to recall the main features of a past experience.
It occurs more commonly in women, progresses rapidly
leading to behavioural disturbances, and death rates are
higher and survival times shorter than in the benign
group. This form of memory impairment is associated with
SDAT.
However the demonstration of two types of senescent
memory impairment does not necessarily imply that they
result from two separate pathological processes. It is
also possible that both are the outcome of a single
process, which if mild results in the benign form, or if
severe the malignant type.
Neuropathological evidence does suggest a link
between AD and normal ageing. The senile plaques,
neurofibrillary tangles and granulovacuolar degeneration
of AD, are also found in the brains of the majority of
healthy people over 65 years of age who show no evidence
of dementia (83-85,87). These changes are relatively
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uncommon in people under 65, but thereafter increase in
frequency with age (85)„
The senile plaques and neurofibrillary tangles appear
to have an identical structure in AD and normal ageing.
However they are found in much greater abundance in AD, and
the degree of dementia is quantitatively correlated with
their numbers (83,84,86,87). The Newcastle group (83,84,
87) found a threshold effect for senile plaques, beyond
which some degree of dementia usually occurs, and Roth (84)
concludes that on present evidence, SDAT is the result of
an acceleration of the changes associated with senescence.
Recent biochemical studies have yielded conflicting
results about the relationship of AD to normal ageing.
Bowen et al (88,89) reported a marked reduction of
choline acetyltransferase (CAT) activity in AD but not in
histologically normal brain from non-demented elderly
people. However Perry and her colleagues (90), while
agreeing that CAT activity is significantly reduced in AD,
also found a decrease in normal individuals with advancing
age. They reported that CAT activity decreased
significantly as the mean senile plaque count rose in both
AD and normal old people (91-93).
The increased risk of developing AD in first degree
relatives of affected patients is frequently used to
support the distinction between AD and normal ageing.
However both conditions could result from an identical
pathological process initiated by environmental factors.
The genetic predisposition to AD could operate by
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increasing individual susceptibility to these factors or
by determining a more severe pathological reaction to
them.
32
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THE GENETICS OF PRESENILE DEMENTIA OF THE ALZHEIMER TYPE:
The evidence for the genetic transmission of PDAT has
been reviewed by Pratt (94,95), Slater and Cowie (96), and
Jarvik (97).
Since 1929 there have been many reports of families in
which 2 or more members suffered from PDAT (69,98).
Feldman et al (98) reported a family with 13 affected
relatives in 4 generations, but failed to establish
linkage of the hypothetical PDAT gene with abnormal
chromosomes, blood group antigens and finger print
patterns. The onset of symptoms usually developed between
the ages of 30 and 40, and the disease was histologically
confirmed in 4 cases.
Wheelan (99) described a family in which 6
relatives in 2 generations had PDAT. Blood grouping was
carried out on 31 members of the family to test for
possible linkage between the hypothetical disease gene and
blood group genes, but results were inconclusive.
Heston and his colleagues (100) reported a family in
which 19 people were affected in 4 generations.
Histological examination of tissue from 4 brains confirmed
the disease. The age at onset of symptoms ranged from 22
to 52 years with a mean of 37 years, and early onset may
be more common in the familial than the sporadic forms of
PDAT.
Landy and Bain (101) described a family in which 3 out
of 6 siblings and their mother developed FDAT, the disease
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being confirmed by cerebral biopsy in 2 of the siblings.
Interestingly their father and maternal grandfather also
probably suffered from SDAT.
In some cases of familial PDAT features such as
muscle twitching, spastic paraplegia and amyloidosis of
the cerebral vessels are reported, and unlike the sporadic
form there is no female preponderance (95).
The sporadic forms of PDAT, in which a positive
family history is exceptional, are said to form the large
majority of cases, and other workers have studied the
frequency of dementia in the families of such patients.
In a Swedish study, Sjogren, Sjogren and Lindgren
(14) studied the relatives of 36 PDAT patients, in 18 of
whom the diagnosis had been histologically verified. They
found that 3 parents and 2 siblings suffered from a
similar presenile dementia, and furthermore 2 parents
and 1 sibling had SDAT. Unfortunately no histological
results were available to confirm the clinical diagnosis
in the secondary cases. In this study, allowing for age
at death, the morbidity risk of developing dementia was
10% for parents and 3.8% for siblings.
In a Swiss study (4) of 97 PDAT patients, which did
not involve field work, the proportions affected with PDAT
and SDAT respectively were for parents 1.4% and 2.8%, for
siblings 3.3% and 0.47%, and for children 1.6% and 0.8%.
Cases of SDAT among the relatives of patients with
PDAT were also found by Lauter and Meyer (3).
Heston and Mastri (102,103) investigated the
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relatives of 30 patients with a clinical and histological
diagnosis of PDAT, and found 22 secondary cases among 301
first degree, and 556 second degree relatives. A post¬
mortem confirmed the diagnosis in 6 of the secondary cases.
In 2 of the confirmed secondary cases, the patients were
aged 70 and 76 at the earliest possible onset of the
disease. They also reported a significantly increased
incidence of Down's syndrome (trisomy 21) and myelopro¬
liferative disorders (leukaemia, Hodgkin's disease, lym¬
phosarcoma, multiple myeloma) among the relatives. These
results are particularly interesting in view of the high
proportion of patients with Down's syndrome who develop
Alzheimer's disease if they survive into their late
thirties (60-62), and also their greatly increased chances
of developing leukaemia (104).
Heston and Mastri (102,103) speculate that micro-
tubular organisation could be adversely affected by a
genetic defect, causing a predisposition to Alzheimer's
disease, trisomy 21, and myeloproliferative diseases.
36
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THE GENETICS OF SENILE DEMENTIA OF THE ALZHEIMER TYPE:
This subject has been well reviewed by Pratt (94,95),
Slater and Cowie (96), and Jarvik (97).
It has long been recognized that genetic factors are
implicated in SDAT. In 1925, Meggendorfer found 18
secondary cases of SDAT among first degree relatives of 60
patients with histologically confirmed SDAT (96).
Weinberger in 1926 found a higher incidence of SDAT among
the relatives of senile dements than in the general
population, and later Cresseri made similar findings (96).
The largest and most systematic study of the genetics
of SDAT was made by Larsson, Sjogren and Jacobson (105) in
Sweden. They investigated the genealogy of the first
degree relatives of 377 SDAT patients which involved field
work in the case of 256 families.
They found a total of 60 secondary cases: 17 among
the parents (unaffected 703), 37 among the siblings
(unaffected 1577), 5 among the spouses (unaffected 300),
and 1 among the children (unaffected 786). On the basis
of these findings, Larsson, Sjogren and Jacobson estimated
that the morbidity risk for SDAT was increased 4.3 times
among siblings and parents of patients with the disease,
compared to the general population at corresponding ages,
and there was steady approximately linear increase of the
morbidity risk with age. The increased incidence among
relatives was not due to their greater expectation of
life, as they had no more than average longevity.
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The Swedish workers found no enhanced morbidity risk
for other psychoses, and claimed that no cases of PDAT or
Pick's disease occurred among the relatives. This claim is
curious as in 10 of their secondary cases, dementia
started before the age of 65.
Because of the apparent absence of intermediate
forms between SDAT and normal senescence among the un¬
affected relatives, Larsson, Sjogren and Jacobson proposed
that SDAT was determined by a single major autosomal gene
with partial penetrance carried by 12% of the population.
A group of Swiss workers (4) also found that the
frequency of SDAT in the first degree relatives was about
four times that found in relatives of patients with
multi-infarct dementia. Of 229 SDAT patients, the
proportions affected with SDAT and PDAT respectively were
for parents 2.22% and 0%, for siblings 3.4% and 0.43%, and
for children 3.24% and 2.16%.
Further evidence that genetic factors are clearly
important in the disease has been presented by Kalman et
al (106), who studied 108 pairs of twins in which the
index twin suffered from SDAT. The incidence of the
disease was 42.8% in the monozygotic twins, compared with
8% in the dizygotic twins, 6.5% in the siblings, and 3.4%
in the parents.
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1) The increased risk of developing the disease in
the close relatives of some patients with PDAT and
SDAT, and the higher concordance rate for SDAT in
monozygotic than in dizygotic twins, is strong
evidence that genetic factors predispose to AD.
2) The exact mode of inheritance is unclear, and
there may be genetic heterogeneity. The results of
single family pedigree studies suggest that the
familial form of FDAT is transmitted as a regularly
manifested autosomal dominant trait. However the
results of the studies into the sporadic forms of
PDAT and SDAT are less easily interpreted, and are
consistent with two genetic modes of transmission :
autosomal dominant inheritance with low penetrance,
or multifactorial inheritance.
3) The occasional occurrence of both PDAT and SDAT
in first degree relatives within individual families
supports the hypothesis that the presenile and senile
forms of AD share a common genetic predisposition.
4) However the lack of full concordance for SDAT
in monozygotic twins indicates that non-genetic
factors are of aetiological importance in AD.
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AGE-RELATED CHANGES IN THE IMMUNE SYSTEM:
The increased prevalence of the disease with age, and
the presence of identical neuropathological features in
inany non-demented elderly subjects, has led to speculation
that AD results from an acceleration of the changes
associated with normal ageing (107). One theory of ageing
links the process to changes in the immune system, as
there is considerable evidence that immune functions decline
with age.
The primary lymphoid system (spleen, thymus, and
lymph nodes) undergoes atrophy after puberty which
continues throughout adult life into old age (107-111).
Paradoxically however, there is an accumulation and
accentuation of lymphoid tissues in the bone marrow,
salivary and thyroid glands, lung parenchyma and liver
with increasing age (107,108), and lymphoid cell
infiltrations have also been found in the ageing brains
of hamsters (112) and humans (113).
Mackay (108) postulates that the increase of this
lymphoid tissue is the result of pathological events such
as autoimmune reactions in response to changes in cell¬
ular proteins with age.
Humoral immunity, as measured by circulating anti¬
body titres to a range of bacterial and viral antigens,
and the primary response to extrinsic antigens, gradually
declines with age (107-109,111,114-116). This decline
is thought to be partly due to age-related intrinsic
deficiencies in the cells directly involved in antibody
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formation (116). However serum immunoglobulin (Ig) G
and IgA levels are increased (117-119), and there is also
an increased incidence of paraproteinaemia with age (119-
122). The proportion of bone marrow derived lymphocytes
(B cells) is increased in the peripheral blood (109, 123-
127), but it is not clear if there is a corresponding
increase in absolute numbers.
However the major cause for the impairment of immune
function with age is the decline in cell-mediated immunity
(CMI). Pre-existing and primary delayed hyper sensitivity-
type reactivity declines (107-109,125,128-130), and
hyporesponsiveness may be associated with reduced life
expectancy in old age (130). The percentage of peripheral
thymus dependent lymphocytes (T cells) is decreased (123-127,
131,132), which appears to be due to a drop in actual
numbers. T cell function probably declines (108,109,117,
124,125,130,133,134), and the proportion of null cells
(lymphocytes that lack T and B cell receptors) are
increased (135).
The decline in CMI may be mediated by the involution
of the thymus gland (107-109,136), which appears to play
an important role in ageing. Neonatal thymectomy in mice
results in impairment of CMI, autoantibody formation, wast¬
ing and death, but has minimal effect on Ig levels except
Ig A which decreases (109). The capacity of the murine
thymus to influence T cell maturation also declines with
thymic involution (137).
As humoral and cell-mediated immunity decline with age,
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there is an increase in the prevalence of autoantibodies
(107,108,117,124,138-142). Nandy (143-145) reported
a progressive increase in the accumulation of brain-
reactive antibodies in the sera of mice and humans as a
function of age. A serum gamma globulin fraction which
binds to cytoplasmic constituents of neurons in sections
of human brain tissue, with increased frequency and in¬
tensity with age, has also been described (146). Field
and Shenton (147) reported that ageing in mice and humans
is associated with the emergence of new antigenic
determinants in the tissues similar to those found in
scrapie mouse brain and spleen, although this finding has
not been confirmed.
The increased frequency of autoantibodies and the
diminished antibody responses with age, may be related to
the decline in suppressor T cell activity (148-150).
Amyloidosis, which is thought to have an immune
aetiology, is frequently found in old age (151-155),
particularly in the brain (153), heart (153,154,156-161),
seminal vesicles (153,158) and pancreas (153,154,162).
Schwartz and his colleagues reported that senile
plaques are commonly associated with cardiac and pancreatic
amyloid in the senium, and proposed that this 'senile
amyloidotic triad' has a common origin from an underlying
metabolic disorder (153,163,164).
Franklin et al (165) found a progressive age-related
increase of serum amyloid A protein in normal people
which rose steeply after the age of 70, although Ignaczak
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et al (166) were unable to confirm this. This led Benson
and his colleagues (167) to propose that 'senile* amyloid
may be of the secondary type, but evidence suggests that
senile amyloid differs according to organ localization
(168-170)c
These age-related immunological abnormalities have
led Burnet (171) and Walford (107,172) to propose their
immune theories of ageing which relate the process to the
accumulation of cell mutations, and the failure of the
immune surveillance system to eliminate them.
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THE IMMUNE SYSTEM AND THE BRAIN:
Under normal circumstances, the blood-brain barrier
which separates blood from the brain and cerebrospinal
fluid (CSF), limits the entry of proteins and their
diffusion into the intercellular space (173,174,175).
The central nervous system (CNS) lacks an organized
lymphatic system, and lymphocytes are scarce as indicated
by the low cell count in normal CSF (173,176). However
the relatively privileged immunological state of the brain
breaks down in some degenerative and infectious diseases
of the nervous system, when antibody, complement,
macrophages, lymphocytes and other cells can enter from
the blood stream to initiate immune responses (173,176).
Raised immunoglobulin levels in the CSF may be
secondary to increased serum antibody levels, as in the
paraproteinaemias, and also to enhanced permeability
following damage to the blood-brain barrier as a result of
disease (173-174).
However raised CSF immunoglobulin levels may reflect
their synthesis by lymphoid cells within the CNS, as in
disseminated sclerosis, and SSFE (173,174,176). These
antibodies show as discreet oligoclonal bands in the





IMMUNE STUDIES IN ALZHEIMER'S DISEASE:
1) Brain antibody studies?
A brain specific antibody was detected in patients
with SDAT by Czech workers, (cited in reference 113), but
Whittingham et al (177) failed to confirm these findings.
Mayer, Chughtai and Cape (178) reported that SDAT
females showed an excess of antineuronal antibodies
compared with SDAT males, or controls.
More recently Nandy (145) found a higher titre of
brain reactive antibodies in PDAT and SDAT patients than
in age- and sex-matched controls.
Tkach and Hokama (179) found higher serum titres of
brain antibody in 3 patients with 'chronic brain syndrome'
compared with controls, but Ingram, Phegan and Bluroenthal
(146) found no difference in the frequency of neuronal
antibody between a similarly described group of patients
and controls. Unfortunately the term 'chronic brain
syndrome' was inadequately defined in both studies, and
therefore the relevance of these results to AD is unclear.
Differing clinical criteria, and variations in
techniques for determining antibodies, may be partly
responsible for these conflicting results.
Brain reactive antibodies (BRA), if confirmed,
could play a primary or secondary role in AD. A breach
of the blood-brain barrier in AD could allow the entry
of pre-existing circulating BRA or provoke its formation,
leading to neuronal damage as the result of antigen-
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antibody reaction. Nandy (144-145) has described a similar
mechanism of brain damage in the mouse following damage to
the blood-brain barrier.
However BRA could also be secondary to the path¬
ological process of AD, and have no aetiological
significance in the disease.
2) Humoral immunity:
Behan and Feldman (180) reported lower serum albumin
and a diffuse increase in serum immunoglobulins in PDAT
and SDAT patients, similar to that found in patients with
primary and secondary amyloidosis. Kalter and Kelly (181)
reported similar findings.
Recently Cohen et al (182,183) detected increased
serum Ig G and Ig A levels in patients with SDAT and
multi-infarct dementia, and a PDAT group, compared with
controls. Eisdorfer and Cohen (184) found that SDAT patients
with lower total serum immunoglobulin concentrations had
significantly lower cognitive test scores, and concluded
that the relative hyperimmunoglobulinaemia along with the
progressive drop of immunoglobulin levels with greater
impairment of cognition, suggested that aberrant immune
functions may be characteristic of these disorders.
Tavolato and Argentiero (185) reported normal serum
levels of Ig A and Ig G, but decreased Ig M and reduced
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numbers of B lymphocytes in 11 patients with FDAT.
Mayer, Chughtai and Cape (178) reported normal serum
immunoglobulin levels in SDAT patients.
Studies of serum autoantibodies in FDAT patients have
failed to find any abnormalities (181,185)„
However the recent detection of oligoclonal bands in
the CSF of patients with PDAT (186,187) supports the
hypothesis that abnormal immunological processes may be
involved in the disease although these may be secondary
rather than primary.
3) Complement system:
No differences in serum complement levels between AD
patients and controls were reported by Mayer et al (178)
and Tavolato and Argentiero (185). Changes in the
frequencies of the C3 groups of the complement system in
PDAT, were found by Mehne et al (188).
4) Cell-mediated immunity (CMI):
Tavolato and Argentiero (185) reported an insignifi¬
cant decrease in the numbers of T lymphocytes, and a
significant increase in the numbers of null cells in PDAT,
compared with controls.
Eisdorfer, Cohen and Buckley (182) found a delayed
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cutaneous hypersensitivity to skin antigens in 9 out of 13
patients with PDAT compared with controls, but skin tests
to determine T-cell functions were normal in a further
study (185)„
The results of 3 in vitro studies to determine T
cell function using lymphocytes from the peripheral blood
of AD patients, have been similarly conflicting (185,181,
187).
5) Amyloidosis;
The term amyloidosis covers a group of disorders with
different clinical features, but which result from amyloid
deposition into organs and tissues (107,165,189-198).
Amyloid formation is the end product of many diseases,
and is thought to be the consequence of impairment of the
immune system. The immune theory is supported by the
results of animal experiments and the association of
amyloidosis with diseases which have immune abnormalities»
The presence of cerebral amyloid in AD further
suggests that immune factors may be implicated in the
disease .
Amyloidosis has been traditionally classified into
primary and secondary forms. Primary amyloidosis occurs
without antecedent or coexisting disease, and is frequently
associated with monoclonal immunoglobulins and Bence-Jones
proteins (165,195,199). Amyloid associated with
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neoplasms involving plasma cells or lymphocytes also
closely resembles the primary form (165,195).
Secondary amyloidosis is associated with a variety of
chronic infections, and connective and neoplastic diseases
in which there is persistent antigenic stimulation with
excessive immunoglobulin production (165,195). Non¬
specific changes involving the gamma or alpha globulin
fractions are sometimes found in the serum (165).
The brain is rarely involved in primary or secondary
amyloidosis (200), and nervous system involvement is
usually confined to the peripheral and autonomic nervous
systems (201-204). However Haberland (200) described a
case of a 49 year old woman with primary systemic
amyloidosis with cerebral involvement who had clinical
features compatible with a diagnosis of AD.
Primary and secondary amyloid consists of two main
components : helical fibrils made up of protein polymers
which constitute 90% of the amyloid substance, and the
plasma (P) component, a glycoprotein which migrates as an
alpha - globulin by electrophoresis (165,194,197,205).
The amyloid fibrils have a similar electron
microscopic appearance, but differ in their main protein
components. In primary amyloidosis, the fibrils are
composed of whole or fragments of immunoglobulin light
polypeptide chains, probably derived from a circulating
(immunoglobulin light chain) precursor (194,206-208). In
the secondary form, the fibrils are composed of the
amyloid A (AA) protein (194,197,209,210) unrelated to
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immunoglobulin, and which is thought to be derived from a
serum precursor called serum AA (SAA) (195-197,211).
Elevated SAA levels have been found in patients with a
variety of acute and chronic infections, connective and
neoplastic diseases, in secondary amyloidosis, and also in
the primary type of amyloidosis associated with multiple
myeloma (165,166,195).
Scheinberg and Cathcart (213) have proposed a unified
concept of amyloid disease in which both primary and
secondary amyloidosis share common pathogenetic pathways,
with macrophage activation representing the initial step.
The primary and secondary amyloid fibrils, although
differing in their main protein components, share an
identical twisted p - pleated sheet configuration which
gives them their property of congo-red staining (197,214).
Amyloid A protein and immunoglobulin light chain
fragments have also been found together in primary and
secondary amyloidosis (215).
The final mechanism of amyloid formation may involve
digestion of the precursor protein by proteolytic
enzymes (194,197,216), although other mechanisms are
possible.
Glenner (198,216,217) identifies 3 types of
cerebral amyloid deposits in AD : congophilic angiopathy,
senile plaques and paired helical filaments.
Congophilic angiopathy has been reported in a
variety of neurological disorders and in non-demented old
people but is particularly associated with AD (39,218).
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An association between amyloid-rich senile plaques and
the severity of congophilic angiopathy was reported by
Mandybur (39). Glenner (217) has recently proposed that AD
is caused by intra-cortical congophilic angiopathy which by
compromising the blood-brain barrier allows a chronic
influx of neurotoxic serum proteins into the brain. He
thinks that the most likely source of the amyloid in
congophilic angiopathy is from the serum, but there could
also be a local protein synthetic abnormality in the cerebral
vasculature leading to the local production of an amyloid-
ogenic compound.
Amyloid is an important component of senile plaques,
although it is sometimes absent. Horst et al (219) have
suggested that there are 4 consecutive phases in their
formation, with the plaques containing no amyloid
representing the terminal phase.
The origin of plaque amyloid is unknown. Divry and
more recently Schwartz (153,164) and Horst et al (219)
have proposed that brain amyloid is a manifestation of a
generalized senile amyloidosis, and that amyloid is the
direct toxic cause of neuritic degeneration and senile
plaque formation. However amyloid is not neurotoxic and
Wisniewski ( 36 ) postulates that plaque amyloid is a
secondary phenomenon to neuritic degeneration.
Attempts have been made to determine the biochemical
nature of senile plaque amyloid. Powers and Spicer (221)
found that it resembled apudamyloid, but Bartoli,
Antonutto and Bianchi (222) found that it had many
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features of immuno - amyloid. Recently Ishii and
colleagues (223-224) reported that plaque amyloid in AD
contains fragments of immunoglobulins, as found in
primary amyloidosis, which strongly suggests that
immunological mechanisms are involved in their aetiology.
Glenner (216) has discussed the possible origins of
the amyloid core. Amyloid could be synthesized and
precipitated locally in the brain as the result of an
antigen-antibody reaction following prolonged
sensitisation to an antigenic stimulus, for example a virus,
as the brain has the capacity for independent immunoglob¬
ulin synthesis. Amyloid could also be a synthetic
product of the phagocytic cells, or arise from the
proteinaceous debris of the degenerated neurites present
at the plaque periphery.
Alternatively amyloid could arise following
deposition of plasma proteins from the blood stream, as
there is evidence of a circulating precursor of
immunoglobulin-type amyloid protein. Recently Miyakawa
and colleagues (225,226) suggested that senile plaque
amyloid is produced by the basement membrane of blood
vessels, and speculated that antigen-antibody reactions
between the blood and vessels may be important.
The intracellular paired helical filaments also
contain protein with the typical twisted p - pleated
sheet fibrils of amyloid (198,217,36 ).
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SLOW VIRUS INFECTIONS OF THE CENTRAL NERVOUS SYSTEM:
The concept that some slowly progressive degenerative
human diseases of the central nervous system (CNS) may be
caused by slow virus infections has been accepted only
recently, after kuru and Creutzfeldt - Jakob disease (CJD)
were shown to be transmissible diseases (227). However it
has long been known that scrapie, a degenerative disease
of the CNS in adult sheep, is caused by a virus (228-230).
Gagdusek (231) has described the general criteria of
slow viral infections:
1. A long initial period of latency, lasting for
several months to several years.
2. An ultimately fatal illness after the appearance
of clinical signs.
3. Primary anatomical lesions limited to a single
organ system.
4. Noninflammatory pathology.
5. Absence of immune response.
6. Limited range of susceptible hosts.
7o Often a heredofamilial pattern of infection.
Slow virus infections of the CNS caused by unconventional
viruse s:
Four degenerative diseases of the CNS, grouped under
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the generic term 'subacute spongiform encephalopathies'
(229,231-239) are now known to be caused by unconventional
viruses: scrapie, and transmissible mink encephalopathy in
animals, and kuru and CJD in man. They have similar
clinical and neuropathological features, and are caused by
very unusual viruses with close biological and physical
properties (231-235). These diseases have long incubation
periods of months or years, and pursue an unremitting
progressive course leading to death. Pathology is
restricted to the CNS, particularly the grey matter of the
brain. The brains show diffuse neuronal loss, neuronal
vacuolation, astrocytic hypertrophy and proliferation,
leading to spongiform changes (status spongiosus) of the
grey matter. In man, amyloid plaques are also sometimes
seen.
These diseases are caused by stable viruses which are
far more resistant to inactivation by ultraviolet light,
and to treatment with formalin or heat, than are
conventional viruses. They have never been seen with the
electron microscope although they are large enough to be
detected. They elicit no inflammatory response in the CNS
nor in other organs in which the virus may be present.
Patients remain afebrile, and the viruses do not elicit an
antibody response in naturally or experimentally infected
animals. Humoral and cell-mediated immune responses of
the host are normal. The viruses, which are closely
associated with membranes and inactivated when such
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association is broken, have been propagated in vitro in
cell cultures derived from the brains of infected animals,
but they do not show any cytopathic effect. The diseases
are transmissible to experimental hosts with long incu¬
bation periods.
There has been considerable speculation on the nature
of these transmissible agents (231,233-235). Suggestions
include that they are self-replicating membrane fragments
which lack nucleic acid, viroids, satellite viruses which
activate or are themselves activated by a helper virus
latent in the susceptible host, or are common viruses
which have become modified in some way as is thought to
happen with the measles virus in patients with subacute
sclerosing panencephalitis. It is conceivable that
scrapie, transmissible mink encephalopathy, CJD and kuru
are caused by a single agent modified by different hosts
(232).
Slow virus infections of the CNS caused by conventional
viruses:
It has long been appreciated that neurological
damage can occur as the result of acute infection with
conventional viruses, particularly the arborviruses and
herpes simplex virus, but it is now recognized that some
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conventional viruses can also produce slow virus infections
of the CNS which fulfil many of Gajdusek*s criteria (227,
232,235-238).
Subacute sclerosing panencephalitis (SSPE) and
progressive multifocal leukoencephalopathy (PML) are
examples of human slow virus diseases caused by
conventional viruses which result in progressive
degenerative disease of the CNS. However they differ in
some respects from slow virus diseases with unconventional
viruses (240): the viruses have an RNA or DNA type of
nucleic acid, and induce specific immune responses. A
virus-associated inflammatory response is evoked in the
brain, and the virus can be seen under the electron
microscope.
Kuru, CJD, SSPE and PML are rare disorders, but they
are important paradigms for the study of other chronic
human degenerative CNS diseases of unknown aetiology such
as AD.
At first sight, the possibility that a slow virus is
implicated in the aetiology of AD seems very speculative.
However the disease has some features compatible with such
a hypothesis, and it is important to point out that kuru
and CJD were also called heredo-degenerative disorders
before being recognized as slow virus infections.
These four examples of human slow virus CNS
infections will now be reviewed to illustrate the concepts
of slow virus disease, and to briefly examine the possible
mechanisms by which apparently harmless and ubiquitous
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Subacute sclerosing panencephalitis (SSPE) is a rare,
progressive, fatal disease of the CNS, which is thought to
be caused by measles or a measles-like virus (236-238,
241-246).
The disease occurs predominantly in children and
adolescents. In SSPE patients in the United States,
Jabbour et al (247) found that the mean age of onset was
7.2 years, with an age range of 2 to 21 years. Canal and
Torek (248) found similar results. However, SSPE has also
been reported in adults (249).
Freeman (245) has described the typical clinical
features and course of the disease. The initial stage is
characterized by insidious intellectual and personality
deterioration, and later by myoclonic jerks of the
extremities, head and trunk. This is followed by further
intellectual deterioration and progressive neurological
impairment. The myoclonic jerks become more persistent
and repetitive, and dysphagia, rigidity, spasticity,
cortical blindness and sometimes extrapyramidal movements
may occur. In the final stages, there is profound
dementia, stupor, and marked rigidity progressing to a
decerebrate stage. Disturbances in the autonomic nervous
system such as hyperthermia may occur, as a result of
hypothalamic dysfunction. Death is usually from a
terminal bronchopneumonia.
However the clinical features and course of SSPE can
be very variable. About 80% of SSPE patients follow the
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relentless progressive course described above, and die
within 1 to 3 years of the onset of the disease (246). In
a small number of patients, death occurs within a few
weeks of the onset of the symptoms (250), but in others
the disease can take a much more protracted course over
many years in which temporary remissions and short
periods of improvement may occasionally be seen (245,
251-253 ).
The electroencephalogram (EEG) pattern is variable
but typically consists of paroxysmal bursts of high-
voltage diphasic slow wave complexes recurring at 3.5 to
20 s intervals synchronous in all leads (245,246,254).
Frequently the myoclonic jerks are synchronous with these
paroxysmal bursts. As the disease progresses the
complexes may be followed by flattening of background
activity, the so-called 'suppression burst' pattern,
but in some patients sporadic sharp waves are seen (245,
246,254).
The pathological features of SSPE have been
summarised by Sourander and Haltia (255), Freeman (245)
and Agnarsdottir (246). The brain may appear grossly
normal but inflammatory changes are widespread throughout
the grey and white matter on microscopic examination.
They include perivascular cuffing (infiltration of
lymphocytes and plasma cells around arteries and veins),
'
leptomeningeal lymphocytic infiltration, microglial cell
proliferation, astrocytic hypertrophy, gliosis, neuronal
loss, neuronophagia which may lead to cerebral atrophy,
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and sometimes demyelination. Eosinophilic intranuclear
and intracytoplasmic inclusion bodies are often found in
neurons, astrocytes and oligodendroglial cells.
SSPE is an extremely rare disease occurring with a
frequency of about 1 per million childhood population, and
males are affected about three times more commonly than
females (247,248,256). Several reports (248,256) have
suggested an association between rural residence and the
disease but Jabbour and colleagues (247) could not confirm
this. Although two epidemiological studies (247,248) have
suggested some geographical variation in the distribution
of SSPE cases, there is no solid evidence of temporal or
spatial clustering.
No clearcut genetic factors have been identified.
Kurent , Terasaki and Sever (257) reported a possible
association between HLA W29 and SSPE, but this finding has
not been confirmed and family clustering is rarely found
(246). Three reports of the occurrence of SSPE in only
one of identical twins also argues against a genetic
basis (258).
There is considerable evidence that the measles or a
measles-like virus is directly implicated in the aetiology
of SSPE. In his original descriptions of the disease,
Dawson (243,244) suspected a viral aetiology because of
the presence of intranuclear inclusion bodies within the
degenerating nerve and glial cells of the brains of two
patients. In 1965 Bouteille and associates (259), using
the electron microscope, found virus-like particles, in
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the brains of SSFE patients which resembled the paramyxo¬
viruses. These findings were soon confirmed (260-263). In
1967 Connolly et al (264,265) found high levels of measles
virus antibody in the sera and cerebrospinal fluid (CSF)
of SSPE patients, and also measles virus antigen in their
brains. This was confirmed by other workers (266,267)
including Jabbour and Sever (268), and Brody, Detels and
Sever (269), who found markedly elevated serum measles
antibody titres in SSPE patients, but not in their parents
or siblings. These results strongly suggested that the
measles virus was involved in the pathogenesis of SSPE,
and direct evidence was obtained in 1969 when a measles
virus was isolated from cultured brain cells of patients
(270,271).
Agnarsdottir (246) and V. ter Meulen et al (272) have
reviewed present knowledge of the immune system in relation
to the measles virus, and SSPE. Patients appear to have
normal cell-mediated and humoral immune responses to
antigens unrelated to measles, at least in the initial
stages of the disease, but have no in-vivo cell-mediated
immune response to measles virus as measured by skin
testing (273). SSPE lymphocytes retain their in-vitro
capacity to respond to both measles and SSPE-virus-
infected cells, although an inhibitory factor present in
the sera and CSF of some SSFE patients, has been demonst¬
rated which can block this response (274,275).
Dayan and Stokes (276) found immune complexes of
measles antigen, Ig G, and complement, in the brain and
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renal glomeruli of a patient who died of SSPE and suggested
a possible aetiological role for them in the disease.
Measles antigens were also detected in the spleen, liver
and lymph nodes from many parts of the body, suggesting
that the measles or measles-like virus is disseminated
widely throughout the body. The successful isolation of
a measles-like virus from lymph node biopsies of some
patients with SSPE (277) provided further evidence that
infection is not restricted to the brain.
High levels of measles antibodies of the Ig G class
are found in the sera and CSF of patients, and some also
have detectable measles specific Ig M. (267,278,279).
The persistence of measles-specific Ig M suggests that
measles virus antigen persists in the SSPE brain, and
the increased amount of measles Ig G and Ig M in the CSF
as compared to the serum, is evidence that they are
synthesized locally within the CNS (278). The abnormally
high levels of Ig G found in the CSF, have been shown to
consist of oligoclonal bands of antibody directed against
different antigenic components of the measles virus (280,
281).
If a preceding measles infection is aetiologically
important in the development of SSPE, it is difficult to
understand why the disease is so rare, when measles
infection is so common. Clearly other factors related to
host immunity and viral characteristics are probably
involved. For example the majority of SSPE patients
develop measles infection unusually early in life, about
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50% doing so before 2 years of age compared with about 20%
for unaffected children (247,256). The average interval
between measles infection and onset of SSPE is approx¬
imately 5 years (247). The very young person may perhaps
be more susceptible to SSPE following measles infection
because of an immature immune system, or an increased
susceptibility of the brain cells to virus-induced damage.
Brody and Detels (256) speculate that in SSPE patients,
measles infection occurs in the presence of passive
maternal antibody, which prevents a normal immune response
against the measles virus, and allows it to persist.
The SSPE agent probably induces an abnormal immune
response in the host which results in disease, but it is
unclear whether the agent is in fact the classical measles
virus, or a measles-like virus (246,272). There are
several possible ways in which the measles virus might
cause SSPE. Disease could be initiated by the prolonged
presence of classical measles virus in the brain, or
develop when measles infection is coupled with another
viral infection as proposed by Brody and Detels (256).
Alternatively, following infection, the measles virus
could become modified in the host during replication.
This could result in a mutant neurotropic measles strain
which remains latent in the brain cells, being unaffected
by high measles antibody levels. Later, reactivation of
the mutant virus could occur to produce a slow infection,
and subsequently SSPE. A further possibility is that SSPE
results from direct infection with an unusual, highly
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neurotropic measles or measles-like virus, but the lack of
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PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY:
Progressive multifocal leukoencephalopathy (PML) is a
rare, subacute, usually progressive demyelinating disease
of the brain (236-238,282-284). It usually occurs in
association with diseases such as leukaemia, lymphomas,
sarcoid, tuberculosis, Hodgkin's disease, and carcinomas
which impair the immune system, or following the use of
immunosuppressive drugs in the treatment of disorders such
as systemic lupus erythematosus or after renal
transplantation (284-287). However PML can also occur
in the absence of any associated disease (288-290).
PML was first described by Astrom, Mancall and
Richardson in 1958 (285), and its main clinical and
pathological features have been summarised by Richardson
(284). Multiple foci of demyelination are found through¬
out the white matter of the brain, particularly the cere¬
bral hemispheres, with relative sparing of the axis
cylinders., These are surrounded by enlarged
oligodendrocytes, many of which contain intranuclear
inclusions and abnormal nuclei, and by giant bizarre
astrocytes, which often contain mitotic figures and
intranuclear inclusions. Less frequently, demyelinating
lesions may be found in the grey matter of the cerebral
cortex.
Most cases occur between the ages of 50 and 70, the
average age being 56 (284). Because of the widespread
nature of the lesions, a wide variety of neurological
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features may be seen. Typically, they include intellectual
and personality deterioration, other mental changes,
disturbances of vision, language and gait, and hemiparesis.
The EEG usually shows non-specific abnormalities (283):
focal slow wave (delta or theta) activity occurs
initially which becomes diffuse as the disease progresses.
The terminal stage of the disease is characterised by
dementia, motor deficits, and finally coma. Death usually
occurs within 3 to 6 months of the onset (284), although
a few cases have been reported in which the disease has
had a more gradual evolution or has undergone remission
(291,292)c
In 1965 Zu Rhein and Chou (293), and independently
Silverman and Rubinstein (294), identified virus-like
particles in the oligodendrocytes of PML brains with the
electron microscope, which resembled papova virions.
Padgett et al (295) in 1971, cultivated a new papova
virus from the brain of a case of PML complicating
Hodgkin's disease, which they called JC virus after the
initials of the patient from whom it was isolated. The
JC virus has been isolated from further cases of PML
since, and is the papovavirus most frequently associated
with the disease (296,297). In 1972 Weiner and
associates (298,299) isolated a different papovavirus from
the brains of two patients with PML. As this new
papovavirus resembled Simian Virus 40 (SV40), it was
called SV40-PML.
Gardner et al (300) have also isolated a new
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papovavirus from the urine of a renal allograft recipient
free from neurological disease and called it BK after the
patient. The BK virus has not yet been related to any
disease (301). PML is the only human disease in which the
JC and SV40-PML viruses have been directly implicated
(301). However the JC and BK viruses are oncogenic in
some experimental animals (302), and the papovaviruses may
also have similar potential in the human brain (303).
Serological surveys indicate that subclinical
infections with JC and BK viruses are very common, and
mostly occur in childhood (304-306). However antibody to
SV40 virus is uncommon in man, and titres are low if
present, except in those who have received contaminated
poliovirus and adenovirus vaccines, or have had contact
with rhesus monkeys (307).
The evidence strongly suggests that PML is caused by
an opportunistic papovavirus infection which usually
occurs in an immunosuppressed host, and results in the
destruction of oligodendrocytes and the demyelination of
the brain. A recent study (308) has shown that as well as
having a general impairment of cell-mediated immunity,
PML patients also show a specific defect in cell-mediated
immune response to the JC virus. Whether the disease
results from activation of a latent papovavirus in the
brain or other tissues, or from viral invasion of the CNS





Kuru is a progressive fatal disease of the central
nervous system (CNS), found only among the Fore people and
their neighbours in the Eastern Highlands of Papua, New
Guinea (231,232,236-238,309). This region was isolated
from the outside world before 1947, and the disease was
only first accurately described by Gajdusek and Zigas
(310) in 1957.
The word kuru means "shivering" or "trembling" in the
Fore language, and accurately describes one of the
clinical features of the disease. It occurs predominantly
in women and children, and is much less common in adult
males. The disease is characterized by a cerebellar
ataxia (gait, truncal and limb ataxia), a shiver-like
tremor and dysarthria. Other features include pyramidal
and extrapyramidal signs, and behavioural changes. As the
disease advances a confused and agitated state may develop
and in the final stages the patient exhibits gross
incoordination, muscle weakness, slurring of speech,
dysphagia, urinary and faecal incontinence, and dementia.
Death usually occurs within a year of the onset of symptoms.
At post-mortem the body is usually wasted, and pneumonia
is often the immediate cause of death.
The histopathological lesions are restricted to the
CNS, and primarily the grey matter of the brain (311).
There is diffuse neuronal loss, with astroglial and
microglial hypertrophy and hyperplasia. Vacuoles form in
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neurons, and the cerebral cortex takes on a spongy
appearance (status spongiosus). Amyloid plaques which
resemble those seen in Alzheimer's disease, old age, and
scrapie, are found in significant numbers particularly in
the cerebellum in two thirds of cases (312). Myelin
degeneration mainly involving the spinocerebellar and
pyramidal tracts, is another feature, and the walls of the
blood vessels may show thickening and perivascular
accumulations of mononuclear cells. No pathology is
evoked in other organs of the body.
Kuru was at first considered to be a genetically
determined disease. There was nothing to suggest that it
was caused by a slow virus. The lack of febrile response,
the failure to detect any antibody response during the
illness, and the absence of acute inflammatory lesions in
the brain was against a viral aetiology. However in 1959
Hadlow (313) pointed out the close similarities of the
disease with scrapie disease in sheep, which was known to
be caused by a transmissible agent with a long incubation
period. This prompted further attempts to establish
infection as the cause of kuru.
In 1966 Gajdusek, Gibbs Jr., and Alpers (314)
demonstrated that chimpanzees inoculated intracerebrally
with bacteria-free suspensions of human brain from kuru
patients, developed a kuru-like disease 18-30 months
later. The clinical and neuropathologica1 features of
the disease closely resembled that of human kuru victims,
although the areas of brain most adversely affected
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varied in the two species. In human kuru the greatest
damage was found in the cerebellum and its connections,
whereas in experimental kuru the cerebral cortex was most
severely affected. Since 1966, primary and serial
transmissions of the disease have been successfully
achieved in rhesus monkeys, mink and ferrets, as well as
chimpanzees (231,315-317). The kuru virus has been found
in low titres in the spleen, liver and lymph nodes, as
well as in high titres in the brains, of human and chim¬
panzee kuru victims (231,316,318). The disease has been
produced in chimpanzees by the intracerebral, intravenous,
intramuscular, subcutaneous and intraperitoneal routes,
but not orally, after incubation periods of 11 months to
8.5 years (318).
When first described kuru was responsible for
approximately 150 deaths a year, which at that time
represented 1% of the total population (310). However in
certain Fore tribes the prevalence of active kuru reached
5-10% of the population (310). At one stage 90% of all
deaths in adult women were caused by kuru (231).
Gajdusek (232) has suggested that kuru is transmitted
by autoinoculation with infected brain at cannibal
ceremonies. Apparently ritual cannibalism, the practice
of eating one's dead relatives as a rite of mourning,
was introduced into the area about 1920, and it has been
suggested that kuru may have originated from a rare
spontaneous case of Creutzfeldt-Jakob disease that spread
through the Fore people because of this custom (232).
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Recently a case of Creutzfeldt-Jakob disease was diagnosed
and confirmed by cerebral biopsy in a native who lived in
the Central Highlands of Papua, New Guinea, about 100
miles from the kuru region (319).
Women conducted the butchery of the dead bodies, and
brain tissue was squeezed to a pulp in bamboo cylinders,
and then steamed. Apparently adult men rarely participated
in this ceremony and seldom ate the flesh of dead kuru
victims. Infection probably occurred as the result of
conjunctival, nasal and skin contamination with highly
infectious brain tissue (231). Since the practice of
ritual cannibalism was abandoned, the kuru rates have
steadily declined particularly in women and children, and
were estimated to have killed about 20 people in 1976.
Gajdusek (231) has estimated that kuru will be eliminated
by 1988o
Kuru has been observed among people born in the
endemic area many years after they migrated away, and the
incubation period of the disease appears to vary from 4
to 30 years (318). Attempts to link the kuru agent to
known viruses, including CMV, have been unsuccessful (320).
Despite its obvious viral cause, genetic factors have
also been thought to be important in the aetiology of kuru
(321). Kuru victims commonly have a family history of the
disease (310), and it is well recognized that breeds of
sheep vary in their susceptibility to scrapie (322).
Kitchin and his colleagues (322) reported an association
between the Gc Aborigine gene and kuru, but Simmons et al
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(323) found no association between the disease and any




CREUTZFELDT - JAKOB DISEASE:
Creutzfeldt - Jakob disease (CJD) was first described
by Creutzfeldt in 1920, and independently by Jakob in 1921.
The subject has been well reviewed by Kirschbaum (324) and
May (325), and Brown and coworkers (326) have recently
published an analysis of the clinical features of 124
cases of histologically proven CJD. CJD (236-238,309) is
a rare butworldwide progressive and fatal disease of the
central nervous system which affects both sexes equally.
Most cases occur between the ages of 35 and 65 years with
an average age at onset of 60 being reported by Brown et
al (326). The prodromal symptoms can be vague : for
example, headaches, dizziness, irritability, insomnia,
depression, poor concentration, apathy, forgetfulness,
weight loss and seIf-neglect. Typically these are soon
followed by involuntary movements (myoclonic jerks) and
dementia, and other less constant findings include
extrapyramidal, pyramidal, cerebellar, sensory and lower
motor neuron signs (324-327). Classically the
electroencephalogram shows diffuse slowing with periodic
bursts of high-voltage slow waves. Death usually occurs
from intercurrent infections between 4 months and 2 years
after onset of the symptoms.
In their series of patients, Brown et al (326) found
that the evolution of the disease was gradual in most
cases, but in about a fifth, the onset was sudden. The
mean illness duration was 8.5 months but this was heavily
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influenced by the few cases which lasted from 2 to 10 years.
In many patients who had a sudden onset, the course of the
disease was rapid, with death occurring within 1 to 2
months.
The neuropathologica1 changes of CJD resemble kuru,
and occur mainly in the cortical and subcortical grey
matter (324,325). They consist of diffuse neuronal loss,
astroglial and sometimes microglial hypertrophy and
hyperplasia, and neuronal vacuolation which leads to
status spongiosus. Amyloid plaques showing some
similarities to those seen in kuru, scrapie and Alzheimer's
disease, are also found in CJD brains particularly in the
cerebellum, in a minority of cases (328,329). Traub et al
(312) for example, reported that 12.7% of 126 patients
with CJD had such plaques.
Daniel (330) classifies CJD into 4 major types based
on the distribution of lesions : the Jakob, Heidenhain,
diffuse and ataxic forms.
In the Jakob type dementia is associated with painful
sensations, spasticity of the limbs, and sometimes
muscular atrophy. Although usually present throughout the
cortex, the brunt of the degeneration of nerve cells falls
most heavily on the cortical regions adjacent to the
central sulcus, in the corpus striatum, thalamus and motor
nuclei of the brain stem and spinal cord.
In the Heidenhain type, the pathological changes are
most severe in the occipital region of the cortex, and
changes are often also seen in the striatum and cerebellar
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cortex. This type is associated with disturbances of
vision, sensation, ataxia and dementia.
Nerve cell degeneration and astrocytic proliferation
are widespread throughout the cortex, basal ganglia,
thalamus, mid brain, cerebellum and spinal cord in the
diffuse type, and the majority of patients with CJD fall
into this group.
The cerebellum is the most severely affected part of
the brain in the ataxic form, and ataxia is the most
obvious clinical feature.
However there are some patients who show features of
each group, and cannot be easily classified.
Klatzo et al (311) pointed out the close similarity
of the pathological lesions observed in the brains of
patients with kuru and CJD, and attempts at transmission
of the disease were soon made following the success with
kuru. In 1968 Gibbs and his associates (331) reported
that biopsy material taken from the brain of a patient
with CJD induced a similar fatal subacute spongiform
encephalopathy in a chimpanzee 13 months after inoculation.
Since then, CJD has been successfully transmitted to
chimpanzees, monkeys, cats, guinea pigs, hamsters and
mice (312,332,316,318). The lymph nodes, liver, kidney,
spleen, lung, cornea and cerebrospinal fluid of patients
with CJD have been shown to harbour the virus in low
titres, but the highest titres are found in the brain and
spinal cord (318). The disease has been induced in some
chimpanzees and monkeys inoculated peripherally by the
subcutaneous, intraperitoneal, intramuscular and
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intravenous routes, as well as the intracerebral route
(318).
CJD is a rare disease occurring in under 1 per
million population (333-335,339). Genetic factors are
suggested by the familial clustering of disease (334-339),
and the increased incidence of the disease in Libyan-born
Jews (340)o In a worldwide epidemiological study of 1435
patients with CJD, Masters and his colleagues (335) found
that 15% of the cases were of the familial type. However
a common source of exposure to the virus or vertical
transmission of the agent, are alternative explanations
for this apparent familial and racial clustering.
Brown et al (341) examined sera from CJD patients and
chimpanzees for antibody titres to a number of known
viruses including CMV, but no consistent pattern was
found.
The question of the transmission of CJD remains
unanswered. Some epidemiological surveys of CJD have
failed to find any spatial or temporal clustering of cases,
although other reports have suggested spatial clustering
(333-335,342,343). Gtrabow et al (319) reported the case
of a man developing CJD only 10 weeks after visiting
Papua, New Guinea, implying that kuru and CJD may share a
common pathogenic agent, and conjugal occurrence of the
disease has been reported twice (344). CJD has been
accidentally transmitted from human to human via corneal
transplantation (345), and stereotactic intracerebral
electrodes (346). There is also the possibility of
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accidental transmission of CJD to a neurosurgeon who died
of the disease (312).
Scrapie causes a disease indistinguishable from CJD in
several species of monkeys. This has led to the suggestion
that CJD could be transmitted through eating incompletely
cooked scrapie-infected hog brains (347) and sheeps eyes
(348) although the evidence for this is scanty, and the
worldwide pattern of scrapie does not correlate with the
distribution of CJD (335). Transmissibility of CJD to the
domestic cat raises the possibility of an animal reservoir
of infection (312), and a tenuous association of the
disease with the keeping of ferrets has been reported (349).
Previous surgery, particularly neurosurgery, and preexisting
neurological disease, may increase the risk of developing
CJD (335).
As kuru and CJD have clinical, pathological, and
viral similarities, Traub and his colleagues (312)
speculate that the two diseases may be caused by different
strains of similar viruses. CJD has been observed in
combination with a wide variety of other chronic
neurological disorders (335) and in AD (329). Traub et al
(312) postulate that CJD might be due to an opportunistic
infection, which results from the invasion or perhaps
reactivation of a latent virus, in a brain already





VIRUSES AND ALZHEIMER'S DISEASE;
Although there is little direct evidence at present to
support the involvement of viruses in the aetiology of AD,
their implication in other forms of dementia does suggestsuch a
possibility. In fact, there are some histological and
biochemical features of AD which are compatible with a viral
aetiology.
Neurofibrillary tangles have been reported in diseases
such as SSPE, herpes and rabies infections, and CJD, in
which a viral aetiology has been confirmed (350). De Boni
and Crapper (351,352) reported that paired helical fila¬
ments (PHF) morphologically resembling neurofibrillary
tangles, are induced in cultured human foetal cortical
neurons after exposure to an extract prepared from brain
affected with Alzheimer's disease, and postulated that the
PHF are a response of human neurons to an infectious
agent.
Amyloid plaques with some similarities to those seen
in AD, are sometimes found in CJD (312,328,329) and kuru
(312), and similar amyloid plaques have also been detected
in the brains of mice inoculated with some strains of
scrapie (353,354), frequently in association with blood
ve sseIs.
The enzyme choline acetyltransferase which is reduced
in the brains of patients with AD, is also reduced in
murine scrapie (355).
The presence of nuclear bodies, a frequent
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neuropathological feature of virus infection, has also
been reported in the brain of a patient with AD (356),
although this finding has yet to be confirmed.
However attempts to implicate viruses in the
aetiology of AD by transmission of the disease to
experimental animals has met with only limited success,
Goudsmit and his colleagues (357) failed to transmit the
disease to primates from 52 patients with AD, although a
spongiform encephalopathy was transmitted in 2 cases.
Although the possibility of laboratory contamination
cannot be ruled out, this suggests that agents which
produce spongiform encephalopathy in primates may be
harboured in the brains of some patients with AD.
This evidence is admittedly circumstantial, but does
raise the possibility that infectious agents, perhaps
conventional viruses acting in concert with an
unconventional agent or a disordered immune system, could
play an aetiological role in AD. The brain is especially
vulnerable to viral damage, because of its high energy
requirements, low rate of DNA synthesis, extensive
neuronal connections, and the inability of neurons to
regenerate (238,358).
The herpes group of viruses, particularly herpes
simplex virus (HSV), varicella zoster virus (VZV) and
cytomegaloviruses (CMV), have properties which make them
potential candidates for slow virus infection of the CNS
(359,360,240,361).
Infection with these viruses are common, and most of
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the population have detectable serum antibodies against
them by middle age. They are neurotropic, and can persist
within the nervous system in a latent form without overt
disease for many years after primary infection. However
reactivation of the virus from a latent state can occur
despite the presence of circulating antibodies and disease
ensue. For example, VZV persists in a latent state in
sensory ganglia, following chicken pox in childhood, but
can undergo reactivation, replication and transportation
down the sensory ganglia many years later to produce the
skin lesions of herpes zoster (359,360). Similarly some
cases of herpes simplex encephalitis which can cause
permanent memory impairment (362,363) may result from
reactivation of the HSV from a latent state within the
nervous system (240,361). Despite these characteristics,
few studies of the possible role of conventional viruses
in AD have been made.
Libikova and colleagues (364,365) found increased
serum and CSF antibody titres to HSV 1 in demented
patients compared with controls, and isolated the virus
from the CSF of two dements. Lycke Norrby and Roos, (366)
also reported an increased incidence of HSV antibodies in
a group of senile and multi-infarct dements. However
Lord et al (367) failed to confirm these findings, but
found significantly higher levels of serum antibodies to
adenovirus in demented patients than controls.
Unfortunately as no attempts were made to differentiate AD
from multi-infarct dementia, no firm conclusions can be
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drawn from these serological surveys about the possible
role of conventional viruses in AD. Edinburgh workers
(368) measured serum antibodies to a number of viral and
bacterial antigens in 14 patients with PDAT, but found no
obvious associations. However Sequiera et al (369),
using nucleic acid hybridization techniques, detected HSV
1 genome in the brains of three elderly patients, two of
whom suffered from SDAT.
Lycke, Norrby and Roos (366) found a significantly
higher incidence of CMV antibodies in patients with AD and
multi-infarct dementia, compared with a control group,
but concluded that differences in the standards of hygiene
and age between the dements and controls may have been
partly responsible. However, apart from the small
Edinburgh study (368), there have been no attempts to
replicate these findings.
The increasing prevalence of CMV antibodies with
advancing age has prompted Weller (370) to ask in relation
to this virus, if we should:
"not look for the visceral counterpart of the
neurocutaneous lesions of zoster, perhaps manifested by
transient fever, hepatitis, pneumonitis, nervous system
involvement, or less overt symptoms?"
One of the purposes of this study is to examine the
possible role of the CMV, whose properties are reviewed in





The cytomegaloviruses (CMV) are double-stranded DNA
viruses which belong to the herpes-virus group (370-380).
They were first isolated in 1956, and derive their name
from their ability to produce large cells (cytomegalic
cells) containing intranuclear and cytoplasmic inclusion
bodies in epithelial cells. They also produce a specific
cytopathic effect in tissue culture.
Human strains of CMV differ in antigenic structure,
but it is unclear if they vary in their pathogenic
potential. All strains share common group-specific
complement-fixing (CF) antigens (381).
CMV infection is common (376, 380-382), and occurs
predominantly in infancy and early adult life, when it is
usually subclinical (374,375). About 50-60% of the
population have detectable CMV antibodies by the age of
30, although this figure is higher in populations who
live in poor, unhygienic and overcrowded conditions (376,
380-382). The persistence of antibodies in the adult
population suggests that following primary infection, the
CMV persist in a latent form inside cells without the
production of new infectious virus. However the latent
virus can undergo reactivation much later to produce new
infectious virus with resulting clinical disease (374).
The prevalence of CMV antibodies is increased in old
age (376,380,382,366), but it is not clear if this is the
consequence of acquiring new infections or reactivation of
latent infections following the age-related decline in
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cell-mediated immunity.
The CMV are not highly contagious, and close and
prolonged contact is necessary for infection (373,374).
The commonest route of infection in adolescents and young
adults is by direct oral contact, but spread may also
occur through contact with infected urine, faeces, and
breast milk, and perhaps through sexual intercourse (373,
374) .
Humoral immunity as determined by circulating antibody
to CMV is normal in CMV infections, but cell-mediated
immune responses to the virus are impaired (383-394).
Most CMV infections are either asymptomatic or mild
in nature, but some are associated with clinical disease:
1. Congenital CMV infections:
The incidence of primary CMV infection in pregnant
women is about 1-2%, and in about half these cases, babies
are born infected, and excreting CMV (373,374,395).
Most babies with congenital CMV infection are
asymptomatic, or have relatively mild features, such as
prematurity, low birth weight, failure to thrive, jaundice,
hepatosplenomegaly, purpura and pneumonia (373,374,395,
398). However about 10% of these ultimately develop
mental retardation, visual and hearing defects and
congenital heart disease (373,374,395,398,399-401).
Severe congenital CMV infections can result in
intrauterine death or cytomegalic inclusion disease.
Cytomegalic inclusion disease (374,376,380,396,397)
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presents shortly after birth with a variety of clinical
features including jaundice, hepatosplenomegaly, thrombo¬
cytopenic purpura, pneumonia, chorioretinitis, haemolytic
anaemia, congenital heart defects, microcephaly,
encephalitis, hydrocephalus, and intracranial calcific¬
ation. Most survivors have severe brain damage, resulting
in psychomotor and mental retardation, epilepsy, palsies,
blindness and deafness. Much of the tissue damage
results from the direct cytopathogenic effect of the
virus but immune abnormalities may also be contributory.
2. Acquired infection in children and adults;
CMV infections have been implicated in atypical
Paul-Bunnell-negative glandular fever (402-405), hepatitis
(375,386,406-409), pneumonitis (410), pericarditis (407),
autoimmune haemolytic anaemia (411,412) and the post-
perfusion syndrome (413-417). CMV infection, either newly
acquired or following reactivation, can be a serious and
sometimes fatal complication of intensive immunosuppres¬
sive therapy in conditions such as leukaemia (418-422),
Hodgkin's disease (418,421), and renal transplantation
(423-431).
CMV infections have also been reported in association
with a variety of neurological disorders involving the
peripheral and central nervous systems.
They are a well established cause of polyneuritis
(Guillain-Barre syndrome) (432-437). Dowling, Menonna and
Cook (436) found serological evidence of recent CMV
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infection in 30 out of 92 patients with polyneuritis.
Schmitz and Enders (435) reported that CMV infection
preceded the onset of polyneuritis in 10 out of 94 patients,
and Duchowny, Caplan and Siber (437) described a patient
in whom systemic CMV infection was complicated by a
brachial plexus neuropathy.
CMV have also been implicated in acute and chronic
encephalitis (437-441).
CMV encephalitis is rare in immunologically normal
adults. Philips et al (441) reported the occurrence of
acute CMV encephalitis in a man and a woman with normal
immune systems. Viral cultures of urine, and
cerebrospinal fluid (CSF) yielded CMV in both cases as
did a brain biopsy specimen in the woman. However serum
CMV CF antibody only reached a titre of 1:16 during and
after the illness in the roan, and no antibody could be
detected in the serum of the woman.
Duchowny, Caplan and Siber (437) also reported the
case of a 30 year old previously healthy doctor who had a
relapsing chronic CMV encephalitis with a clinical
history extending over several years. Yanagisawa,
Toyokura and Shiraki (442) described a 51 year old
housewife with double encephalitis due to herpes simplex
virus (HSV) and CMV. They postulated that in the course
of a necrotizing - encephalitis by HSV, the debilitated
state and treatment with steroids and antibiotics
promoted a CMV infection in the brain.
CMV encephalitis is usually associated with
immunosuppression. Schneck (443) found evidence of CMV
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encephalitis in 12 out of 34 immunosuppressed patients who
had died following kidney transplantation. Glial nodules,
predominantly in gray matter, and consisting mainly of
microglial cells with occasional astrocytes were found in
11 cases. Inclusion bodies and cell changes compatible
with CMV infection were noted in 2 brains. Dorfman (440)
described the neuropathological findings in the brains of
4 adults with CMV encephalitis, three of whom had under¬
gone renal transplants and immunosuppressive treatment.
All 4 patients had widespread glial nodule encephalitis
thus confirming Schneck's findings. Two of the brains
also contained cytomegalic cells with prominent intra¬
nuclear inclusions.
There have been few attempts to study the effects of
CMV on the nervous system of animals. Brain damage
resembling that found in human cytomegalic inclusion
disease has been induced in suckling mice by intracerebral
inoculation with mouse CMV (444). Wroblewska et al (445)
reported the development of an acute demyelinating disease
in a chimpanzee more than 3 years after intracerebral
inoculation at birth of brain cell cultures derived from a
patient with multiple sclerosis. A strain of CMV was
isolated from the left frontal lobe of the animal but it
is possible that it was transmitted from other chimpanzees





The HLA* or major histocompatibility system of man
consists of a group of closely linked genes located on the
short arm of chromosome 6, at 4 loci designated A, B, C
and D (figure I), which appear to play a central role in
the regulation of important biological functions (446-450,
452,453,455,457).
Although many gene alleles are possible, only one
allele is found at each locus at any one time. At present
20 alleles at the A, 33 at the B, 6 at the C, and 11 at
the D loci are recognized, although more probably await
recognition at the C and D loci (459).
The products of these genes are called HLA antigens.
The HLA-A, -B and -C antigens are glycoprotein structures
found on the surfaces of all nucleated cells of the body
including leucocytes and T and B lymphocytes, and
comprise 1-2% of cell membranes (460-462). They develop
in the foetus at about 6 weeks and persist throughout
life. They consist of two polypeptide chains: a light
chain with a molecular weight of 12,000 daltons called f>2
- microglobulin, coded for by a gene on chromosome 15, which
is non-covalently linked to a heavy chain with a molecular
weight of 43,000. The heavy chain bears the antigenic
*H for human; L for leucocyte, the first cells
shown to carry antigens of this system; and A

























determinants which confer HLA specificities on the
molecule by variation of its aminoacid sequences (460-
462).
The combination of HLA antigens on each chromosome is
called a haplotype. Therefore each person has two
haplotypes, and millions of HLA antigen combinations are
possible (463). Both parents contribute one haplotype
each to their offspring resulting in four possible
haplotype combinations (462).
The HLA -A, -B, and -C antigens are detected
serologically by a microlymphocytotoxic technique using
lymphocyte suspensions prepared from peripheral blood
(455,460,462). The lymphocyte suspensions are delivered
by micropipette to wells containing standardized antisera
to each specificity, and complement is added. The
antibodies used do not occur naturally, but are found in
the sera of people such as pregnant women, blood
transfusion and transplant recipients, who have been
exposed to foreign HLA antigens. Lymphocytes bearing a
particular HLA specificity are killed when exposed to its
specific antibody, the number of dead cells being estimated
visually or automatically using a fluorescent dye or
radioactive technique. Individuals have a maximum of two
antigens at each HLA locus, although sometimes only one is
detectable because they are homozygous or have a
determinant as yet unidentified.
The D-locus antigens are identified using the more
complicated mixed lymphocyte culture (MLC) technique (455,
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464)» More recently HLA -DR (D-related) antigens which
appear to be closely related to the D-locus antigens,
have been defined serologically by lymphocytotoxicity in
B-lymphocyte enriched suspensions (461,465). Typing for
HLA-C and DR antigens is not done routinely at present
because antisera are not widely available. Similarly as
the MLC is a complicated technique, the identification of
D-locus antigens is restricted to a few laboratories.
Much of our understanding of the importance of the
HLA system has been derived from the study of the H-2
complex (453,457,466), the equivalent genetic region in
the mouse.
Products of the genes within the H-2 system are known
to participate in immune responses to viruses, code for
major transplantation antigens which are involved in graft
rejection, mediate protection against intracellular
bacterial infections and regulate certain cellular-immune
responsiveness assessed by antibody production (454). The
H-2 system has also been implicated in the genetic control
of lifespan in congenic mice (470).
Genes within the HLA region also appear to play a
central role in the control of immune responses in man
(447, 448,450,453,457,460,463). In particular Ir (immune
response) genes have been defined and arguments put forward
that these may be identical with the la genes in the mouse
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and hence with the homologous DR antigens in man.
The Ir genes are thought to control T-cell responses
to antigens by influencing the proliferation and function
of helper-T cells, suppressor-T cells, and cytotoxic-T
cells, and also T cell -B cell, and T ce11-macrophage
interactions (454,456 )„ Recent findings suggest that the
major histocompatibility system also plays an important
role in cell-cell communication and differentiation of
non-lymphoid as well as lymphoid cells, as it has been
implicated in phenomena such as intercellular adhesion,
contact inhibition, lymphocyte recirculation and stem cell
growth (458).
Although not coding for antibody molecules, the HLA
region probably influences their production through the
interaction of helper-T cells with B cells.
HLA genes also control the synthesis of some
components of the complement system (C2, C4, factor B)
(453,457,468), and HLA antigens play an important role in
the rejection of organ transplants (455,469).
A number of human diseases have been found to be
associated with particular HLA antigens (449,451,471-473),
although the reasons for such associations are unclear.
Dausset (474) has described the features which commonly
characterise these HLA-associated disorders:
1) They are of unknown aetiology.
2) No causal agents have been identified, although
in some cases, viruses have been suspected.
3) They are often hereditary, but with weak
104
polyfactorial and probably polygenic penetrance.
4) Disease susceptibility is transmitted within
families, but the segregation does not follow simple
mendelian laws.
5) Frequently there are immunological
abnormalities such as cellular infiltrations in the tissue
lesions, circulating antiviral antibodies, or autoanti¬
bodies.
6) The course of the diseases are usually subacute
or chronic.
7) The diseases are seldom manifested before adult¬
hood, and there is little impact on reproduction or
selection.
Most HLA associations are with the B-locus antigens,
but some diseases show even stronger associations with the
HLA-D/DR antigens. This is because of linkage
disequilibrium (463,475), the tendency for certain HLA
antigens at different loci to occur together more
frequently on the same haplotype than expected by chance,
the stronger association occurring the closer the
particular HLA locus is to that for the disease suscept¬
ibility gene.
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Two main approaches are used in HLA studies (473):
Population studies:
Population studies involve the comparison of the
frequencies of HLA antigens in a group of patients with a
particular disease, with the corresponding frequencies in
a group of healthy unrelated controls of the same ethnic
origin. A positive association between a disease and a
particular HLA antigen occurs if the frequency of the
antigen is increased in the patients compared with the
controls.
The relative risk (RR) - the number of times more
often the disorder develops in persons possessing this
antigen as compared to those in whom it is absent - is
always greater than one in positive associations, and
gives some measure of the biological significance of the
association.
Population studies have successfully identified a
number of HLA-associated diseases, including ankylosing
spondylitis, Reiter's disease, certain sero-negative
arthropathies, psoriatic arthritis and acute anterior
uveitis which are all associated with HLA-B27 (451,472,
473), juvenile-onset diabetes with HLA-B8, B15, Cw3, Dw3
and Dw4 (451,472,473), and multiple sclerosis with A3, B7
and Dw2 (451,472,473).
The relative risk for most diseases is under 10, but
people with HLA-B27 have a relative risk of about 80 of
developing ankylosing spondylitis (472).
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Family studies:
If more than one member of a family is affected by
the disease family members can be HLA typed to see if
affected relatives share haplotypes more often than
expectedo Although not commonly used, family studies
allow the possibility of detection of linkage of disease
genes to HLA genes even if an association is not found in
the general population.
There are some grounds to expect that AD might be
associated with an HLA antigen, as the disease shows
many of the typical features of HLA-associated disorders.
A positive association would improve our understanding of
AD by confirming the involvement of genetic factors and
helping to identify their nature. It might also help to
clarify the relationship between PDAT and SDAT, and
would be further evidence that immune factors may be
implicated in the disease, as many of the HLA-associated
disorders are thought to be immunologically mediated.
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ABO AND RHESUS BLOCD
GROUPS AND DISEASE
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ABO AND RHESUS BLOOD GROUPS AND DISEASE:
Many red blood cell groups have been defined, but the
ABO and rhesus blood groups are clinically the most
important, and have been most frequently used as genetic
markers in the search for blood group and disease
associations (476 )„
ABO BLOOD GROUPS;
In man, 4 major ABO blood groups are recognized (477,
478) - A, B, AB and O - which are determined by the presence
or absence of the antigens A, B and H on red blood cells.
These antigens are also found in most secretions and
tissues of the body except the central nervous system,
and are controlled by 3 allelomorphic genes A, B and O
located on chromosome 9 (479).
ABO genes are thought to control the synthesis of
transferase enzymes which catalyze the formation of
polysaccharides, which combine with lipids to produce cell
surface glycolipids (478). It is thought that a basic
substance H, which is present in all red cells, is mostly
converted into group A and B antigens by their respective
transferases which are coded for by the genes A and B. The
O gene is considered to be an amorph or silent gene, with
no detectable effect on the H substance.
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ABO BLOOD GROUPS AND DISEASE:
The ABO blood group antibodies have been directly
implicated in haemolytic disease of the newborn (480) and
haemolytic transfusion reactions (481). However there is
also evidence to suggest that persons with different ABO
blood groups vary in their susceptibility to certain
diseases (476,482-484), although the increased risk is
generally small.
In ABO and rhesus blood group and disease association
studies, patients with a particular disease are blood
grouped, and the frequencies of the different groups are
then compared with those among a control group of people
unaffected by the disease. An association is suggested if
the disease is increased significantly in patients of a
particular blood group. The most striking findings, which
have been confirmed in many studies, are the increased
frequencies of blood group A and 0 in patients with
gastric carcinoma, and duodenal and gastric ulceration,
respectively (482,483,485-487). The increased risk of
persons developing these diseases with the appropriate
blood group varies from 1.2 - 1.4 times. Clarke et al
(488) found an even closer association between the
hereditary character of nonsecretion of ABH substances in
the saliva, and duodenal ulceration.
Associations of blood group A with coronary
thrombosis, pernicious anaemia, smallpox and malaria have
also been claimed (476)„
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Unfortunately the accuracy of many of the positive
findings of ABO blood group and disease association
studies is questionable. Some of the significant results
are derived from single studies, and the data obtained
from multiple studies often show very large discrepancies.
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RHESUS BLOOD GROUPS;
The rhesus (Rh) blood group system is thought to be
determined by 3 pairs of closely linked genes (C, D and E,
and allelic forms c, d and e) (489), which are inherited
as a group on chromosome 1 (479). A combination of these
three genes which code for the Rh antigens (C and c, D and
d, and E and e) found on red blood cells, are inherited fr
each parent (489).
Thirty six genotypes are possible, and on testing
with the appropriate Rh antisera, the population can be
subdivided into 15 Rh phenotypes (489). However the D
antigen is clinically the most important of the Rh system
because of its greater capacity to stimulate antibody
formation.
In Rh typing, only anti-D serum is usually used to
classify persons Rh negative or Rh positive. Rh negatives
are homozygous for the d gene, and Rh positives are either
homozygous DD, or heterozygous Dd.
Rh BLOOD GROUPS AND DISEASE:
Incompatibility with respect to the Rh antigens is an
inportant cause of haemolytic disease of the newborn (480)
and haemolytic transfusion reactions (481). Both disorder
result from Rh antigen - antibody incompatibility.
However, the Rh blood groups, like the ABO blood
groups, may influence susceptibility to some diseases in a
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less direct way. Statistically significant increases of
Rh negatives have been reported in typhoid and paratyphoid
infections, mumps, infectious mononucleosis, viral
meningitis, tuberculous infections of bones and joints and
the genito-urinary system (476), and multiple sclerosis
(490).
The reservations made about the accuracy of many of
the positive findings of ABO blood group and disease
association studies apply equally to rhesus blood group







a ) Case Finding:
The study patients were selected from unrelated
inpatients at five psychiatric hospitals in the Yorkshire
region.
Potential study patients were identified following
consultation with medical and nursing staff. Their case
notes were examined, and any patients who lacked details
of past medical and psychiatric histories, or the results
of appropriate physical examination and laboratory
investigations, were excluded.
For consideration, patients had to fulfil the
following criteria.
b) Selection criteria;
Senile dementia of the Alzheimer type:
1. A history of dementia with an insidious onset
after the age of 64, and a slowly progressive impairment
of memory, intellect and personality.
2. No previous psychiatric or occupational history
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which might account for the dementia - e.g. alcoholism,
drug abuse, drug overdoses, gassing, boxing.
3. No family history of other dementias such as
Huntington's chorea.
4o No previous history of significant physical
disease which could have caused dementia - e.g. epilepsy,
strokes, brain tumours, hypertension, peripheral vascular
disease, diabetes.
5. Clear evidence of dementia on clinical examination.
6. Absence of significant cardiovascular disease or
focal neurological signs.







Serum vitamin B±2 snd folate,
Serum WR or VDRL,
Urinanalysis,
Chest and skull X-ray,
ECG.
Some patients had been further investigated with
EEG's, air encephalography, brain and CAT scans, and the




Presenile dementia of the Alzheimer type;
lo A history of dementia, starting insidiously
before the age of 65, with early memory impairment and
disorientation, parietal lobe features such as apraxia and
aphasia, and progressive impairment of memory, intellect
and personality.
2. No previous psychiatric or occupational history
which might account for the dementia - e.g. alcoholism,
drug abuse, drug overdoses, gassing, boxing.
3. No family history of other dementias such as
Huntington's dhorea.
4. No previous history of significant physical
disease which could have caused dementia - e.g. epilepsy,
strokes, brain tumours, hypertension, peripheral vascular
disease, diabetes.
5. Clear evidence of dementia on clinical examin¬
ation.
6. Absence of significant cardiovascular disease or
focal neurological signs.







Serum vitamin B12 folate,
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Serum WR or VDRL,
Ur inanalysis,
Chest and skull X-ray,
ECG.
c) Assessment of patients:
Patients who satisfied these criteria were interviewed,
and their mental and cognitive state assessed. Cognitive
abilities were formally tested with the Mental Test Score
(83), although some patients were too demented to co¬
operate .
This was supplemented by information from the nursing
staff about their behavioural functioning such as ability
to dress, feed and communicate.
Patients who showed clear evidence of dementia were
then physically examined to confirm the absence of
significant cardiovascular disease or focal neurological
signs. Any outstanding laboratory investigations were
completed, and data for the study recorded from the case
notes of the patients.
A total of 125 patients who satisfied the criteria
for Alzheimer's disease were selected for study. However
a postmortem on a male patient in the SDAT group failed to
confirm the clinical diagnosis and he was excluded from
the study.
The characteristics of the 124 patients are shown in
Tables 1 and 2.
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A 15 year old girl with a clinical diagnosis of
Creutzfeldt-Jakob disease later confirmed at postmortem,
was also studied, but this case will be described
separately.
d) Identification of secondary cases of AD;
The case notes rarely contained details about the
occurrence of AD in other family members, and field work
was necessary to obtain this information.
The next of kin of 10 HLA-B15 positive and 10 HLA-B15
negative patients matched for sex and age at onset of AD,
and also 14 other HLA-B15 positive patients, with no
recorded family history of AD in their case notes, were
interviewed at home when a physical and psychiatric
history of the first degree relatives was compiled.
A diagnosis of AD was made in the relatives if a
history of progressive dementia in the absence of strokes
or other significant physical disease was elicited.
However this study was not comprehensive, as in some
cases, contact had been lost with individual family
members, or information about deceased relatives was
lacking.
The two relatives affected with dementia who were
still alive, were traced, HLA-typed and ABO and Rh blood
grouped.
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e) Follow up of patients:
In order to determine if HLA antigens influence life
expectancy in AD, patients were revisited about 18 months
after completion of the serological studies. The case
notes of those who had died were traced from medical
records, and the date of death recorded.
SEROLOGY
a) Specimens;
About 30 mis of venous blood was collected from each
patient in a lithium heparin and 2 plain glass tubes.
These specimens were taken to the Leeds Regional Blood
Transfusion Centre for blood grouping and HLA typing, and
to the Leeds Public Health Laboratory for estimation of CMV
antibody titres.
b) HLA Typing:
One hundred and twenty five patients were tested for
20 of the main HLA-A and -B group antigens using the
National Institutes of Health (NIH) lymphocytotoxicity
technique (462) (Appendix 1).
All the HLA specifities were determined using at
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least 3 well-defined antisera (Appendix 2).
c) ABO and Rh Blood Grouping:
The ABO and Rh (D) blood groups of 125 patients were
determined using standard agglutination techniques (491).
d) CMV Antibodies:
Sera were stored at -20° C until tested, and examined
for antibodies to the CMV complement-fixing (CF) antigens.
The complement fixation test used was a modification of
that described by Bradstreet and Taylor (492), and was
performed by a microtitration technique. Serum dilutions
started at 1 in 16.
CMV antibody titres were determined in only 113 of
the 125 patients, none of whom were on steroids or
immuno-suppressive drugs. The virus study was started
later than the blood group studies, and the other patients
had either died or been transferred elsewhere before sera
could be taken for CMV antibody estimations.
POST-MORTEM STUDIES
AD can be diagnosed with certainty only at post¬
mortem. Therefore post-mortems were requested on all the
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study patients who died at High Royds Hospital, in order
to obtain some measure of the accuracy of clinical
diagnosis, and also to allow for biopsy specimens of the
brain, liver and kidney to be taken for viral studies in
a few cases.
VIRUS ISOLATION ATTEMPTS
Samples from the brain, liver and kidney biopsies of
8 patients were inoculated into human embryonic lung
fibroblasts. These cell cultures were maintained in
Eagle's basal medium with foetal calf serum, 100 units of
penicillin/ml and 100 micrograms of streptomycin/ml at
o
37 C for one month. During this time they were examined
at regular intervals for cytopathic effect (CPE) caused by
cytomegalovirus. Cultures showing no CPE after one month
were regarded as negative for cytomegalovirus.
CONTROLS
a) HLA ANTIGENS:
The control group for the HLA antigen study comprised
a group of 458 normal Leeds blood donors and healthy
hospital staff.
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b) ABO AND Rh BLOOD GROUPS:
The controls for the ABO and Rh blood group study
consisted of a group of new blood donors drawn from
approximately similar catchment areas as the patients, and
were taken from the tables of Kopec (493,494). In addition
the ABO and Rh blood group frequencies of 196 of the 458
Leeds HLA antigen controls were known and used as
controls o
c) CMV ANTIBODY STUDY:
Thirty-nine non-demented patients suffering from
functional psychiatric disorders (mainly schizophrenia)
who had been inpatients at High Royds Hospital for many
years, and who were of a similar age to the study patients,
were selected to act as controls for the CMV antibody
study after being interviewed by the writer . Their
characteristics are shown in Table 6„ The HLA antigen
phenotypes were not determined in this group.
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STATISTICAL PROCEDURES
Differences in the frequencies of HLA antigens and
ABO and Rh blood groups in the patients and controls were
tested with a 2 x 2 chi-square test with Yates'
correction when indicated. When multiple comparisons are
being made, there is an increased chance that a
statistically "significant" probability value will be
observed in respect of one of the comparisons when in fact
there is no real association. Therefore the probabilities
obtained in the HLA study were multiplied by 20, the
number of antigens tested, to give a corrected P value.
Patients were subdivided according to the presence or
absence of HLA-B15, an HLA antigen found to be significant¬
ly associated with AD in this study, and analyzed in
relation to sex, age at onset of disease, length of ill¬
ness, and family history of dementia, to determine if
these clinical characteristics influenced the strength of
the association. Statistical comparisons between these
two groups were made using the Student's t test and chi-
square test. In the family studies, only relatives
thought to be at risk of developing AD - i.e. those over
44 years of age, the age at which the youngest patient
developed AD in this study - were included in the
analysis of data.
The ABO, Rh and HLA data obtained from similar
studies performed at different centres were combined with
data from this study using Woolf's method of statistical
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analysis (521,522). Woolf's method allows a more
accurate assessment of the relative risk and statistical
significance of any association between AD and these
genetic markers to be made, and also tests for hetero¬
geneity between centres.
The prevalence of CMV antibodies in the patients and
the controls were compared using the chi-square test.
The data on CMV antibody titres were transformed to
logarithms to the base 10, and the differences in the mean
titres of the patients and controls were determined
using the Student's t test. Titres that were less than
16 were taken to be 8 for the purposes of statistical
analysis.
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THE ROLES OF THE WORKERS ENGAGED IN THE STUDY
In the study, the case finding, the psychiatric and
physical assessment of patients, the collection of
serological specimens and their delivery to the
laboratories, the field work with relatives and the
follow-up of patients, were made by the writer.
The HLA typing and blood grouping, and the virology
studies, were performed by the technicians of the Leeds
Regional Blood Transfusion Centre, and the Leeds Public
Health Laboratory, respectively. The postmortems were






1) General information on the patients studied:
Tables 1 and 2 show the sex, age at onset of the
disease, ABO and Rh blood group, HLA type, and CMV
antibody titre of the patients in the FDAT and SDAT
groups respectively, and also the length of the disease
and the histological diagnosis if known, of the dead
patients in these groups.
Table 3 shows some of the data from tables 1 and 2
in summary form, and also the mean age at onset in the
presenile and senile groups. There is an excess of
senile patients and women in the study, which reflects
the greater prevalence of the senile form of AD and also
the female preponderance found in this disorder.
Tables 4 and 5 show the mean age at onset in the
male and female presenile and senile patients respectively.
No significant differences are found between the men and
women.
2) General characteristics of the patients and
controls for the CMV study;
Table 6 compares some of the characteristics of the
patients and controls for the CMV study. There are more
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men than women in the control group, but the mean ages of
the patients and the controls at the time of study do not
differ significantly.
3) ABO blood group frequencies in the patients
and controls:
Table 7 shows the frequencies of the ABO blood groups
in the patients and controls. No significant differences
in ABO blood group distributions are found between the
patients and controls.
4) Rhesus blood group frequencies in the patients
and controls;
Table 8 shows the frequencies of the Rh blood groups
in the patients and controls. The Rh blood group
frequencies in the PDAT group do not differ significantly
from the controls.
However significantly more of the senile patients
are Rh negative compared with the controls of Kopec (494)
(X2 = 6.442, df = 1, P = 0.011), or the Leeds Blood
Transfusion (BTS) controls (X2 = 5.235, df = 1, P =
0.022).
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No significant differences are found in Rh blood
group distribution between the combined group of FDAT
and SDAT patients and the controls of Kopec (494) (X2 =
4,807, df = 2, 0.1> P> 0.05), or the Leeds BTS controls
(x2 r 3.777, df = 2, 0.5>P>0.1).
5) HLA antigen frequencies in the patients and
controls:
The HLA antigen data for the PDAT, SDAT and combined
groups of patients shown in Tables 1 and 2, are
summarised in Tables 9, 10 and 11 respectively.
Table 9 shows that the frequency of HLA-B15 is
significantly increased in the presenile group (32.43% v
13.75%, X2 r 9.224, df = 1, P = 0.0024, corrected P =
0.048), compared with the controls. The frequencies of
the other antigens do not differ significantly.
Table 10 shows that the frequency of HLA-B15 is also
significantly increased in the senile group (26.44% v
13.75%, X2 = 8.837, df = 1, P = 0.003, corrected P =
0.06) compared with the controls. The other HLA antigen
frequencies do not deviate significantly from the
controls.
Table 11 shows that the increase in frequency of
HLA-B15 remains significant when the presenile and senile
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patients are combined (28.20% v 13.75%, - 14.619, P<
0.001, corrected P<0„02), but no significant deviations
are seen with the other HLA antigens.
6) HLA-B15 and clinical characteristics of the
patients:
(i) Frequency of HLA-B15 in men and women:
Tables 9, 10 and 11 show that there are no
significant differences between men and women in the
frequency of HLA-B15, although more women than men have
this antigen in the presenile group.
(ii) HLA-B15 and age at onset of AD:
Figure 2 shows the percentage of patients who are
HLA-B15 positive in relation to their approximate age at
onset of AD.
Tables 12 and 13 show the mean ages at onset of AD
in the HLA-B15 positive and negative presenile and
senile patients respectively. No significant
differences are found between the HLA-B15 positives and
negatives o
(iii) HLA-B15 and length of history of the disease
in the deceased patients;
Tables 14 and 15 show the approximate length of
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history of AD in the deceased PDAT and SDAT HLA-B15
positive and negative patients respectively. No
significant differences are found between the HLA-B15
positives and negatives.
7) Family studies:
Table 16 shows the results of the family studies of
the first degree relatives of 10 HLA-B15 positive and 10
HLA-B15 negative patients matched for sex and age at onset
of disease. Table 17 shows the family histories of AD in
a further 14 unmatched HLA-B15 positive patients.
9.7% of the relatives of the 34 patients studied had
a history of AD, and cases of PDAT and SDAT were found
to occur within the same families.
The frequency of AD in first degree relatives was
significantly higher in the 24 B15 positive patients when
they were compared with the 10 B15 negative patients (13%
v 3.3%, X2- 4.5924, P = 0.0324). However no statistically
significant difference in the frequency of family history
of AD was observed when the 10 B15 positive and 10 B15
negative patients matched for sex and age at onset of
disease were compared (8% v 3.3%, X? = 1.2572, 0.5> P>
0.1) .
Patients numbers 69 and 62 had a similarly affected
relative still alive, and the results of the HLA, ABO and
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Rhesus blood group studies of these two secondary cases
are also shown in Tables 16 and 17 respectively.
An unconfirmed history of leukaemia was reported in
the relatives of patients numbers 50 and 104.
8) CMV antibody titres in the patients and
controls:
Table 18 shows the number and percentage of patients
and controls with CMV antibodies at different titres.
More patients than controls have antibody titres
l/l6, but the difference is not significant (85.84% v
76.92%, X2 = 1.678, df = 1, 0.5>P> 0.1).
Table 19 shows the serum geometric mean antibody
titres (logjo) CMV of the patients and controls. The
mean titre is higher in the patients than the controls,
but the difference is not significant.
Table 20 shows the CMV antibody titres of the HLA-
B15 positive and negative patients. Significantly more
HLA-B15 positive than negative patients have a titre ^
1/64. (57.6% v 26.25%, X2 - 10.027, P - 0.0016).
Table 21 shows the geometric mean CMV antibody
titre of the patients in relation to HLA-B15. The mean
titre is significantly higher in the HLA-B15 positives.
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9) Post-mortem studies:
Post-mortems were obtained on 18 of the 46 patients
who died at High Royds Hospital (tables 1 and 2).
Alzheimer's disease was confirmed in 14 patients,
and mixed AD - multi-infarct dementia diagnosed in 2
further cases. In patient number 2, widespread autolytic
changes due to delayed autopsy prevented a positive
confirmation of the macroscopic diagnosis of AD. The
histological diagnosis of multi-infarct dementia was
made in patient number 125, and he was excluded from the
study. Although consent was not obtained for a post¬
mortem on patient number 12, a cerebral biopsy had
previously confirmed the clinical diagnosis of AD.
10) Virus Isolation Attempts;
Brain, liver and kidney biopsies from patients
number 2, 6, 46, 56, 64, 77, 84 and 98 failed to induce
any CPE in cell cultures.
Age ons< ofi 52 53 64 63 64 51 63 55 63 49 61

























































Age onsi ofJ 55 61 53 64 54 47 62 60 64 64 49

























































Age onsi ofi 59 63 56 53 58 51 60 52 60 45 55



























































*Widespreadautolyticchangesdtel yeautopsyprev nted apositivec nfirmationfthemacrosc picdi gn sisfAD.
**Histologicaldiagnosisfr mbra ni p y.
Age ons< ofI 70 78 79 81 69 68 71 78 75 70
Table2(i)tCharacteristicsofthsenilepatients ABORh Sexbloodl groupHLA type
CMV antibody titre (reciprocal)






















































Age onsi ofi 71 71 77 73 70 78 71 72 78 79 72
Table2(ii).Charact risticsofthesenilepatients ABORh Sexbloodl grouprHLA type
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Age ons< ofj 74 74 72 67 70 73 73 67 66 69 71























































































































































Age onsi ofi 71 74 69 89 81 83 75 80 70 72 68
Table2(viii).Characteristicsofths nilepatients ABORhHLACMVDurationofHistological


































































Characteristics of the patients
PDAT group SPAT group
Number of patients 37 87
Male : Female 13 : 24 37 : 50
Mean age (years) at onset 57.3 73.5











Males Females t value Significance
13 24
56.62 57.63 0.510 p> 0.5












Males Females t value Significance
37 50





CMV study - characteristics of the patients and "controls"
Patients Controls* t value Significance
Number 113 39
Male : Female 47 : 66 23 : 16
Mean age





* Mean length of hospital admission (years) 23.3 ± 13.89
151
TABLE 7




































HLA ANTIGEN FREQUENCIES IN THE FDAT PATIENTS
HLA-A % Controls % FDAT % Male s % Females
(n = 458) (n = 37) (n = 13) (n = 24)
1 37.11 48.65 23.08 62.50
2 49.12 62.16 61.54 62.50
3 25.11 16.22 15.39 16.67
9 17.90 10.81 15.39 8.33
10 6.55 2.70 7.69
11 12.88 8.11 23.08








































































= 9.224, P - 0.0024
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TABLE 10(i)
HLA ANTIGEN FREQUENCIES IN THE SPAT PATIENTS
HLA-A % Controls % SPAT % Males % Females
(n = 458) (n = 87) (n = 37) (n = 50)
1 37.11 29.89 37.84 24
2 49.12 57.47 51.35 62
3 25.11 32.18 32.43 32
9 17.90 25.29 16.22 32
10 6.55 11.49 13.51 10
11 12.88 14.94 18.92 12

















HLA ANTIGEN FREQUENCIES IN THE SPAT PATIENTS
% Controls % SDAT % Males % Females
(n = 458) (n = 87) (n = 37) (n = 50)
9.39 6.90 5.41 8
29.04 28.74 29.73 28
25.20 22.99 24.32 22
30.78 36.78 32.43 40
3.71 1.15 2.70
8.29 4.60 - 8
9.17 5.75 8.10 4
7.02 9.20 5.41 12
12.88 14.94 10.81 18
9.62 13.79 18.92 10
13.75 26.44* 29.73 24
8.30 3.45 2.70 4
2.62 1.15 2.70
8.837, p = 0.003
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TABLE 11(i)
HLA ANTIGEN FREQUENCIES IN THE COMBINED
(PDAT + SPAT) GROUP OF PATIENTS
HLA-A % Controls % Combined % Males % Females
(n = 458) (n = 124) (n = 50) (n = 74)
1 37.11 35.48 34 36.49
2 49.12 58 o90 54 62.16
3 25.11 27.42 28 27.03
9 17.90 20.97 16 24.32
10 6.55 8.87 12 6.76
11 12.88 12.90 20 8.10
28 6.55 5.65 4 6.76
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TABLE 11 (ii)
HLA ANTIGEN FREQUENCIES IN THE COMBINED
(PDAT + SPAT) GROUP OF PATIENTS
HLA-B % Controls % Combined % Males % Females
(n ■ 458) (n » 124) (n « 50) (n = 74)
5 9.39 8.07 8 8.10
7 29 o 04 27 c42 32 24.32
8 25.20 20.16 20 20.27
12 30.78 34.68 32 36.49
13 3.71 2.42 4 1.35
14 8.29 6.45 4 8.10
17 9.17 5.65 8 4.05
27 7.02 8.87 6 10.81
35 12.88 16.13 12 18.92
40 9.62 13.71 16 12.16
15 13.75 28.20* 28 28.38
18 8.30 2.42 2 2.70
22 2.62 0.81 2
















Age characteristics of the HLA-B15 positive
and HLA-B15 negative PDAT patients












Age characteristics of the HLA-B15 positive
and HLA-B15 negative SPAT patients
HLA-B15+ HLA-B15- t value Siqnificance
Number 23 64
Mean age
(years) 74.96 72.92 1.674 0.1>P>0.05
at onset
Range




Length of history of AD in deceased
HLA-B15 positive and HLA-B15
negative PDAT patients
HLA-B15+ HLA-B15- t value Significance
Number
Mean







Length of history of AD in deceased
HLA-B15 positive and HLA-B15
negative SPAT patients
HLA-B15+ HLA-B15- t value Significance
Number 16 34
Mean































































































































































































































































































































to CMV in patients and "controls"
% of patients with reciprocal serum
antibody titres to CMV
< 16 16 32 64 128 256
SDAT + PDAT 14.16 19.47 30.97 23.89 10.62 0.885
patients* (16) (22) (35) (27) (12) (1)
(n = 113)
Controls** 23.08 20.51 17.95 33.33 5.13
(n - 39) (9) (8) (7) (13) (2)
* Mean age at time of study = 73.16 years t 8.959
** Mean age at time of study = 70.1 years - 9.425
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TABLE 19
Serum geometric mean antibody titres
(logjo) to CMV in patients and 'controls*
Patients Controls t value Significance
Geometric 32 27.27
mean titre





to CMV in HLA-B15 positive and
negative patients
% of patients with reciprocal serum
antibody titres to CMV
< 16 16 32 64 128 256
HLA-B15+ 12.1 6.1 24.2 36.4 18.2 3.0
patients* (4) (2) (8) (12) (6) (1)
(n = 33)
HLA-B15- 15.0 25.0 33.75 18.75 7.5
patients** (12) (20) (27) (15) (6)
(n = 80)
* Mean age of B15 positives ■ 73.1 years- 9.992
**Mean age of B15 negatives = 73.2 years - 8.566
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TABLE 21
Serum geometric mean antibody
titres (login) to CMV in B15 positive
and negative patients
HLA-B15+ HLA-B15- t value Significance
Geometric
mean titre 45.73 27.62
(log10) 1.6602 1.4412 2.952 0.01>P>0.001
± 0.392 +0.3444
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11) Creutzfeldt-Jakob disease in an HLA-B15 positive
15 year old girl:
Case history:
The patient D.H. (patient number 126) a female of
West Indian parentage, developed a rapidly progressive
illness at the age of 15, characterised by dementia,
myoclonic jerks, spasticity of the limbs, and muscle
wasting, and died 1 year later.
Tests revealed that she was HLA-B15 positive, and
that she had a CMV antibody titre of l/32, and a poly-
omavirus BK titre of ^ 1/20,480.
Post-mortem results:
Histological examination of the brain was made by
Dr. Harriman, Consultant Neuropathologist at Leeds
General Infirmary, who reported:
"Cerebral cortex: There is widespread spongiform
change, variable in intensity but severe in the frontal,
parietal and occipital regions. The "ground substance"
(i.e. neuronal and glial cell processes) of the grey
matter is pitted by numerous spaces of variable size,
rarely much larger than a neuron. Some contain shrunken
neurons or glial cells. There is considerable loss of
neurons from all laminae, but astrocytes proliferate to
give the cortical ribbon an appearance of excess
cellularity. A small proportion of the astrocytes are in
the swollen form. These changes lead to disorganization
of the laminar pattern. The temporal and insular
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cortices are least affected, and the cornu amraonis
escapes completely. Silver stains of the frontal cortex
confirm the gliosis, and show no evidence of senile
plaque formation or neurofibrillary tangles.
White matter: This is mostly normal. The exception
lies in the parietal white matter, where there is
diffuse myelin pallor, occasional vacuolation of axons
and astrocytosis.
Basal ganglia; Spongiform change with neuronal loss,
and less gliosis than in the cortex, affects the head of
the caudate nucleus and the putamen. Both large and small
neurons are affected, predominantly the latter. The
change is sharply limited to these structures, no
pathological features being found in the globus pallidus
and substantia nigra.
Mid and brain stem: The pons and medulla are normal.
In the cerebellum, the dentate nucleus is not affected.
The folia show separation of the molecular zone from the
granular layer, and the granular cells are rarefied.
This is attributed to artefact.
Comment: Thus the histopathological features are
those of subacute spongiform encephalopathy. It
corresponds with the morphological characteristics of
Creutzfeldt-Jakob disease despite the fact that the age
of the patient is at the lowermost limit of the age
incidence of that condition."
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No virus particles were seen on electron microscopy
and no viruses were isolated after 5 months incubation.
12) PDAT in one of monozygotic twin sisters:
Case History:
The patient M.S. (patient number 10) was admitted to
High Royds hospital on the 15th January 1973 at the age of
57 suffering from dementia.
According to her relatives, her illness started
insidiously about 1964, when she was 49 years of age. At
that time she began to forget the names of friends, and
started to jot down information on pieces of paper to
remind her to do her household duties, or remember where
she had placed various objects. Later, she started to
buy unnecessary goods from shops, and began to neglect
her housework. As her memory loss became worse, she had
v
difficulty in following conversations, and became easily
frustrated and tearful when she got things wrong.
She was admitted to a general hospital psychiatric
unit for investigation of her memory loss in August 1968
when she was 53. On examination, she was noted to be a
neatly dressed grey haired woman, who smiled blandly and
at times was euphoric. She gesticulated a lot, and
tended to fiddle with her ring when she had difficulty in
answering questions. She stuttered considerably and
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interjected a lot of "you know's" to cover up her
difficulties in expression or answering questions. She
was very vague, and it was impossible to get a coherent
history from her»
Her concentration was poor, and she showed severe
impairment of long-term, and to a lesser extent, short-
term memory. Her general information was poor, and she
was disorientated in time, place, and person. She showed
some degree of sensory, nominal and expressive dysphasia,
and constructional apraxia, and she had gross dyscalculia.
There was also evidence of perseveration and
confabulation.
Physical examination showed a plump well-nourished
normotensive woman with moderate arcus senilis. No
obvious abnormalities were found, although it was noted
on neurological examination, that her reflexes were
slightly brisker on the left.
A full blood count, ESR, urea and electrolytes,
liver function tests, blood glucose, serum cholesterol,
thyroid function tests, serum folate and vitamin B12
were normal. A WR and Kahn were negative, and skull and
chest X-rays, ECG, and CSF examination including a Lange,
were normal. An AEG, left carotid angiogram and
radioactive isotope brain scan were also normal. A
series of EEG records were abnormal, being dominated by
activity of theta and delta frequency symmetrically
distributed, and in one EEG, subclinical seizure activity
was observed.
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She was discharged from hospital on 18th October
1968 and her condition continued to deteriorate over the
next four years. Her memory deteriorated, she lost her
capacity to wash or dress herself, and she had to be fed.
She rarely spoke and usually sat all day staring vacantly
into the fire or through the window, although would
sometimes join in the hymn singing on the radio.
Her husband and twin sister devotedly attended to
all her needs, but eventually the task proved too much,
and she was admitted to High Royds hospital in January
1973.
Although occasionally agitated and restless at times
initially, she later became mute, unresponsive and doubly
incontinent. There was a generalized increase in muscle
tone, reflexes were brisk and symmetrical, and plantar
responses were flexor. Later, twitching movements of the
limbs were observed. For about a year before death, she
had difficulty in swallowing, and her weight steadily
declined. She finally became bedridden and required
total nursing care. She died on Boxing Day 1979, of
bronchopneumonia, about 15 years after the onset of
dementia.
Family History of the Twins:
Their parents were unrelated. Both were healthy,
although their mother suffered from insulin-dependent
diabetes in later life. Their father died at the age
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of 65 from pneumonia, and their mother died aged 75 from
heart and renal failure.
Their older sister, and younger brother and sister
are alive and well, and there is no family history of
dementia.
Personal History of the Twins:
Minnie, the patient, and her twin Annie, were born
full-term, after an uneventful delivery. Each weighed
about 6 lbs., and the patient was the second born.
Their childhood was happy. Both were good scholars,
and always achieved similar marks in examinations. They
were identical in appearance, and had similar mannerisms.
However the patient was the more active of the two, and
in her early adulthood, went rock-climbing and pot-holing.
Minnie was also more serious and conscientious than her
sister. On leaving school, they worked at the same mill
as weavers although Minnie was always the better and
faster worker. They were constant companions until
Annie married at 21, and moved away. Minnie married at
22, and never moved out of the area where she was born.
Although parted geographically, the twins remained
very close and visited each other regularly, and went on
holiday together.
Minnie had a daughter now aged 38 who remains well.
Annie also has a daughter aged 40, who has had treatment
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for Hodgkin's disease.
The patient had no serious physical or psychiatric
illnesses prior to the onset of AD, although in later
adulthood became easily upset by stress. Annie has
remained well, and showed no evidence of dementia 18
months after the death of her twin sister.
Confirmation of monozygosity:
The twins were identical in physical appearance
(Figures 3 (a), (b) and (c) ), and were frequently
mistaken for each other.
The results of blood group studies on the twins
shown in Table 22, also strongly suggest monozygosity.
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g. 3 (b). The twins in childhood.
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Fig. 3 (c). The twins in adulthood.
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TABLE 22





























The total chance of dizygosity in caucasion twins
with the above blood groups is approximately 0.02.
HLA antigens Al,B17, A1,B17,
35 35
The probability of M.S. and A.H. being dizygotic
with the above HLA antigens is 0.25.
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Summary of autopsy findings:
" The body was that of an emaciated elderly woman.
All the visceral organs were underweight and there was
a severe bronchopneumonia.
The brain weighed 850 g and externally showed marked
generalized cortical atrophy which was maximal at the
frontal poles (Figures 4 (a), (b) and (c)). On coronal
sectioning the cerebral ventricles were dilated and the
cerebral cortex thinned especially in the occipital
region (Figures 5 (a), (b) and (c) ). The subcortical
structures appeared relatively normal.
Microscopically, senile plaques were found in the
cerebral cortex in representative sections stained by
haematoxylin and eosin from the temporal, frontal,
parietal and occipital regions. Frozen sections of the
temporal lobe, stained by Von Braumuhls silver
impregnation technique, showed that these plaques were
very numerous and many of the cortical neurons showed
neurofibrillary tangles (Figure 6).
The appearances are consistent with the clinical
diagnosis of dementia of the Alzheimer type. •'
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Fig. 4 (a). Superior aspect of the brain of
M.S., showing generalized cerebral
cortical atrophy, with thinning of
the gyri, and widening of the sulci.
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Fig. 4 (b). Lateral aspect of the brain of M.S.,
showing generalized cerebral
cortical atrophy, with thinning of
the gyri, and widening of the sulci.
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Fig. 4 (c). Inferior aspect of the brain of
M.S., showing generalized cerebral
cortical atrophy, with thinning of
the gyri, and widening of the sulci.
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Fig. 5 (a). Coronal section through the fronto¬
parietal region of the cerebral
hemispheres of M.S. showing cortical
thinning and ventricular dilatation.
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Fig. 5 (b). Coronal section through the
parietal region of the cerebral
hemispheres of M.S., including
Ammon's Horn, showing cortical
thinning and ventricular dilatation.
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Fig. 5 (c). Coronal section through the occipital
region of the cerebral hemispheres of
M.S., showing cortical thinning and
ventricular dilatation.
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Fig. 6. Section of the temporal lobe of M.S.,
stained by Von Braumuhl's silver
impregnation technique, showing senile










1) THE CLINICAL DIFFERENTIATION OF ALZHEIMER'S
DISEASE FROM OTHER FORMS OF DEMENTIA:
Unfortunately only a clinical diagnosis of AD can be
made during life. Cerebral biopsy is now considered to be
unethical, and anyway does not always provide an accurate
histological diagnosis. It is therefore necessary at this
point to consider the evidence in support of the validity
of differentiating AD from other forms of dementia on
clinical features alone.
About 85% of the cases of dementia occurring in the
elderly are due to SDAT, multi-infarct dementia (MID), in
which brain damage occurs as the result of multiple small
or large infarcts usually from embolization, or a mixture
of both diseases (87,495-497). In the other 15% of cases
dementia results from other pathological processes, and
roost of these should have been screened out from this
study.
Although frequently overdiagnosed clinically, MID
(498) is distinctly less common than SDAT which is
responsible for the majority of cases of dementia
occurring after the age of 64 (87, 495-497).
Certain clinical features are traditionally held to
differentiate between SDAT and MID (499-501):
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In SDAT, the onset is usually insidious, and insight
is soon lost. Typically there is early deterioration
of memory and personality, and mood changes such as
irritability and blunting of emotion may occur. The
course of the disease is more gradual than MID, and the
incidence of hypertension is no greater than expected in
the general population of a similar age. Neurological
signs usually appear late.
However in MID, the onset is often fairly sudden,
but insight, personality and memory are relatively well
preserved until the later stages of the disease. Anxiety,
depression and emotional incontinence may occur, and
hypertension is frequently present. The course of MID is
fluctuating and often step-like in association with
cerebrovascular accidents and acute episodes of clouding
of consciousness. Focal neurological signs typically
appear early in the disease, and evidence of generalized
arteriosclerosis may be found.
These traditional clinical criteria for distinguish¬
ing between SDAT and MID which were used in the present
study, have been validated by recent clinico-pathological
studies.
Corsellis (495) found broad agreement between the
clinical diagnosis of SDAT and the extent of senile plaques
and neurofibrillary tangles in the brain, and also observed
a similar relationship between MID and the degree of
cerebral vascular changes. However changes of both SDAT
and MID were found in about 20% of the brains.
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The clinical and pathological distinctions between
SDAT and MID were also upheld by the Newcastle workers
(13,84) in a prospective study of demented patients,
although they too found that about 20% of the brains had
mixed SDAT-MID changes (87 )„ They showed that the sever¬
ity of cognitive impairment during life is quantitatively
correlated with mean senile plaque counts, and severity
of neurofibrillary changes in SDAT patients, and the
amount of cerebral softening in MID patients (84).
Threshold effects of pathological change were demonstrable
in both types of dementia below which the brain could
accommodate without obvious intellectual and personality
deterioration but beyond which the clinical picture of
dementia is likely to occur (84). For SDAT, the
threshold value for mean plaque counts was 14 plaques
per field, and for MID, 50 mis of cerebral softening
(84). Ninety four per cent of the patients with a
clinical diagnosis of SDAT were found to have a total
volume of cerebral softening less than 50 mis, but 73% of
patients with a clinical diagnosis of MID had a total of
more than 50 mis of cerebral softening (84).
In an attempt to quantify the MID changes in
demented patients, Hachinski et al (502,503) have
designed a scale based on the traditional criteria for
MID, which rates each patient on an ischaemic score,
and correlated these with cerebral blood flow. Cerebral
blood flow was found to be normal in SDAT but reduced in
MID, and the degree of dementia was inversely related to
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the flow. They conclude that a patient's ischaemic score
successfully differentiates between SDAT and MID, and that
the score differences reflect the greater degree of
cerebral ischaemic damage in MID.
PDAT is the most common form of presenile dementia
(13), but has to be differentiated from Pick's disease
which is much less common. Other forms of presenile
dementia such as CJD and Huntington's chorea are rare.
Traditionally PDAT has been differentiated from
Pick's disease on specific clinical features. Memory
impairment, parietal lobe symptoms such as dysphasia,
apraxia, and agnosia, and disturbances in gait and muscle
tone are said to occur early in PDAT (10); in Pick's
disease, frontal lobe symptoms are described as dominating
the early picture with personality deterioration, emotional
blunting, loss of drive and insight, disinhibited
behaviour, antisocial conduct and incontinence often being
present (504). Memory and intellect are usually well
preserved in the early stages.
Many of these traditional criteria have been validated
by recent clinico-pathologica1 studies. Sim and coworkers
(505-507) performed cerebral biopsies on 56 patients with
presenile dementia, and found that memory impairment,
apraxia, and EEG changes occurred early in PDAT, but late
in Pick's disease, whereas personality changes, incontin¬
ence, fits, psychotic features, confabulation, and
neurological signs occurred early in Pick's but late in
PDATo Todorov et al (508) successfully diagnosed PDAT
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clinically in 28 out of 32 presenile patients who under¬
went post-mortems, using the traditional clinical
criteria of a dementia occurring insidiously before the
age of 65, with early memory and intellectual deteriorat¬
ion, aphasia, agnosia and apraxia with typical evolution
of the disease. Similar clinical criteria were also used
in this study for the diagnosis of PDAT.
There is therefore clear evidence that AD can be
clinically diagnosed with reasonable success using
traditional clinical criteria, but some reservations need
to be made. The clinical differentiation of SDAT from
MID is straight forward when massive focal symptomatology
is present, but is more difficult when these features are
less prominent. Also the differentiation of PDAT from
Pick's disease becomes less easy with time, as their
clinical features tend to merge.
It is perhaps inevitable that some of the patients
included in this study did not have AD. However the
histological confirmation of the disease in most of the
patients who underwent post-mortems would suggest that
their numbers are small, and although diluting the results,
should not significantly affect their validity.
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2) THE PATIENT POPULATION STUDIED
The use of hospital patients in this study should not
limit the application of its findings. Kay, Beamish and
Roth (17) reported little difference in the severity of
dementia of patients in hospitals and institutions and
those living in the community, and found that social and
family factors play a more important role in determining
admission than severity of illness. Inpatients with AD
are therefore fairly representative of the general
population of patients with this disease, and conclusions
drawn from this study should be able to be applied
generally.
However it is important to recognize that spurious
associations between blood groups and disease can result
from genetic stratification in the population, when the
patients belong to a subpopulation in which the blood
group and disease may be more frequent than in the
control group, although they have no causal connection.
Genetic stratification can be ruled out as an explanation
if similar blood group and disease associations are found
in populations of different ethnic origins.
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3) IDENTIFICATION OF SECONDARY CASES
In the family studies, the patient's next of kin had
to be relied on to provide up-to-date information on their
relatives, which in some cases they were not fully able to
dOo
Corroboration of secondary cases of dementia with
hospital records and death certificates proved impossible
in most cases. Most of the secondary cases of dementia
had died or were living some distance away, and only 2
could be personally examined. Independent corroboration
of the disease was obtained in 6 of the 17 secondary
cases of dementia. In 3 cases the disease was
corroborated from hospital case notes, in 2 cases from
hospital case notes and personal examination, and in a
further case from a death certificate.
Although included as an affected relative, there is
an element of doubt about the diagnosis of the father of
HLA-B15 negative patient number 8. The father's hospital
case notes show that he started to dement in his late 60's
about a year after undergoing a prefrontal leucotomy,
which was performed to alleviate his chronic depressive
illness.
Some of the secondary cases of dementia had never in
fact been admitted to hospital, and the hospital records
of others who had been, were destroyed a few years after
their death and were therefore unavailable for scrutiny.
Death certificates were also found to be an
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unreliable means of corroborating dementia. Heston and
Mastri (102) reported similar difficulties, and found that
in 17 out of 30 patients with histological evidence of AD,
the causesof death on their death certificates were given
as "cerebral vascular disease" or "pneumonia".
The difficulties associated with such studies indicate
that conclusions about the frequency of AD in the families
of the patients can only be tentative.
4) THE CHOICE OF THE CONTROL GROUPS
The proper choice of a control group is of the
greatest importance in blood group and disease association
studies, and the controls should be drawn from a
population with a similar ethnic background as the patients.
New blood donors are frequently used as controls although
are not entirely satisfactory. They are self-selected
and therefore it is impossible to be sure how representat¬
ive they are of the general population, particularly as
their home addresses and not their places of birth are
recorded. Self-selection may have the particular effect
of increasing the frequency of Rh negatives among new
blood donors, especially women.
The controls used for the blood group studies are
considerably younger than my patients, but this age
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difference should not invalidate the results. Although
Vogel (509) has claimed that people who are blood group
O are healthier and live longer than those who are blood
group A, other workers (510,511) have found no significant
alterations in ABO and Rh blood group frequencies with
increasing age. Also Bender et al (512), and Hansen,
Sparck and Larsen (513), reported that HLA frequencies
did not alter significantly with increasing age either,
although Macurova et al (514) found that HLAwlO (now
B40) was increased in people over 80 years of age (28.91%)
compared with adults (9.71%) and youths (10%). Yarnell
and colleagues (511) also found good general agreement in
HLA antigen frequencies between a random sample of elderly
people and a control group, although they too reported an
excess frequency of HLA-B40 in the elderly group (20% v
12%). Clearly the use of blood donors as controls can be
criticised, but in the absence of a better control group,
are frequently used in blood group and disease association
studies.
The choice of non-demented chronic inpatients as a
control group for the CMV study is also not ideal. This
group had been in hospital for much longer than the study
patients, and had presumably been more exposed to CMV
infection which is known to be common in institutions.
The possible effects of prolonged psychotropic drugs on
the immune system and viral antibody titres of the
controls, have also been ignored. However their selection
as controls was thought to be better than having no
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control group for the CMV study.
5) BLOOD GROUPING AND HLA TISSUE-TYPING
Technical errors can occur in blood grouping and
tissue-typing if carried out by inexperienced technicians.
Some of the difficulties which may arise in tissue-
typing have been pointed out by Joysey and Wolf (462);
cross-reactions may occur between specific HLA antigens
and it is therefore advisable to use several antisera
for their detection. Other sources of error include
contamination of live lymphocyte suspensions on which the
tissue-typing is carried out.
In this study, blood grouping and HLA-typing were
performed by experienced technicians at the Leeds Regional
Blood Transfusion Centre and three well authenticated
antisera were used to detect HLA-B15. The increased
frequency of HLA-B15 is unlikely to have arisen as the
result of cross-reactions with HLA-B17, B5 and B35, to
which some degree of cross-reactivity with B15 is well
recognized, because the frequencies of these antigens in
the patients did not differ significantly from those in
the controls.
It is therefore unlikely that significant technical
errors occurred, and any minor errors would probably be
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randomly distributed, and not adversely affect the
results.
6) ANALYSIS OF RESULTS
The statistical methodology commonly used in ABO and
Rh blood group studies have been severely criticised by
Weiner (515) and Manuila (516), and their criticisms are
also valid for HLA studies.
False significant results can easily arise from
errors in data collection and their statistical treatment,
and the lower the number of patients included in a study,
the higher the statistical sampling error which can
occur. Data from other centres are commonly pooled for
statistical purposes to overcome the difficulties of
accumulating large numbers of patients at any one centre,
but the logic for doing so has been questioned by Weiner
(515).
In this study patients were tested for 20 HLA
antigens, so that by chance, at least one antigen may be
altered in frequency, either increased or decreased, at
the 5% level of significance in the patients compared with
the controls (473). One way of overcoming this difficulty
is to multiply the P value obtained by the number of
antigens studied to give a corrected P value (473). This
procedure is rather conservative, and true HLA
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associations with disease may be missed. The only
definitive method of confirming an association is for
other independent workers to find a similar association.
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ABO BLOOD GROUP RESULTS
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DISCUSSION
1) ABO BLOOD GROUP RESULTS:
The ABO blood group frequencies of the patients do
not deviate significantly from the controls. Blood groups
AB and B are relatively underrepresented, and group A
overrepresented in the PDAT group, but as the numbers of
patients are small, sampling error may be a possible
explanation for these findings.
The only study of ABO blood groups in PDAT patients
which the writer is able to trace, found no obvious
associations (188), although the frequency of blood group
A was slightly raised as in this study.
Mourant, Kopec and Domaniewska-Sobczak (517) list 12
ABO blood group studies of senile dementia, although many
of these can be criticised because of imprecise selection
criteria and the inclusion of small numbers of patients.
Several studies report an apparent association, but no
consistent pattern is found. Normal ABO blood group
distributions were found in 2 British studies of demented
patients which included SDAT cases (518,519).
The failure of this study to find any significant
association of ABO blood groups with AD, is therefore in
agreement with the findings of most other studies.
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RHESUS BLOCD GROUP RESULTS
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2) RHESUS BLOOD GROUP RESULTS;
This study shows a significant association of the Rh
negative blood group with SDAT, but clearly caution is
necessary in the interpretation of this result, as
relatively few patients were studied. However two other
similar studies of SDAT patients are listed by Mourant,
Kopec and Domaniewska-Sobczak (520), and both found an
excess of rhesus negatives. Data from these and the
present study can be combined using Woolf's method (521,
522) of statistical analysis to allow a more accurate
assessment of the relative risk and statistical significance
of the association of the rhesus negative blood group with
SDAT to be made. Heterogeneity between the three centres
can also be tested with Woolf's formula.
The results of this combined analysis are shown in
table 23. The rhesus negative blood group is found to be
significantly associated with SDAT (pooled X2= 13.778,
dfl, p = 0.0002). There is no significant heterogeneity
between the relative risk obtained in the individual
studies, and it is therefore justifiable to combine the
results of the three studies. The weighted estimated
mean value of the relative risk is 1.9.
Masters (519) also found an excess of rhesus
negatives among a group of elderly patients with "mixed
organic states" which included SDAT.
However a similar association with PDAT would also
be expected if both conditions share common genetic
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factorso The failure to find an excess of rhesus
negatives among the presenile patients in this study may
mean that the SDAT result is spurious, but could also
indicate that a different genotype is present in some
SDAT patients, which is absent in the PDAT group. The
failure of two other studies to demonstrate an
association of the rhesus negative blood group with
PDAT would support the latter hypothesis.
This association, if confirmed, could indicate a
causal relationship, in that rhesus negatives are
intrinsically more likely to develop SDAT. This could
be due to the pleiotropic or multiple effects of the
same gene. For example, one possible explanation for the
association of thromboembolic diseases with blood group
A is that the plasma antihaemophilic globulin is raised
in group A persons relative to that in group O
individuals (484).
Clarke (482) has also suggested that the increased
susceptibility to disease could result from the direct
immunological effect of the blood groups themselves. The
immunological importance of the ABO blood groups for
example, is shown by their influence on tissue survival
in organ transplantation (523).
Blood groups could also influence disease
predisposition by increasing susceptibility to infectious
agents. This theory is supported by reports of
significant associations between blood groups and some
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human infectious diseases. (524-529).
Why humans of different blood types vary in their
resistance to infections is unclear. Some bacteria and
viruses are known to have blood group-like antigens in
common with humans (530-535), and it is possible that
disease susceptibility is partly determined by the
presence of blood group antibodies. An invading pathogen
with an A-like antigen which is partially neutralized by
anti-A antibodies in people with blood group O, could for
example, result in an increased association of the
infection with blood group A individuals who lack anti-A
antibodies.
However the association of the rhesus negative blood
group with SDAT could also be indirect, and result from








































































3 ) HLA ANTIGEN RESULTS:
This study shows a significant association of HLA-B15
with FDAT and SDAT. Table 24 shows the estimated relative
risk (RR) of developing AD when HLA-B15 is present for
each of the patient groups in the study. The RR for the
presenile group is 3, and 2.3 for the senile patients.
Five other HLA studies of AD patients have been
reported (368,536-539):
Henschke, Bell and Cape (536) studied 34 patients
with AD mainly of the SDAT type, for 38 HLA-A, -B, and
-C antigens. Only the frequency of HLA-Cw3 was
significantly increased over controls (38.2% v 21.6%,
P< 0.05, RR 2.3), but the findings lost significance
when correction was made for the number of antigens tested.
Cohen, Zeller, Eisdorfer and Walford (537) studied 25
patients with unspecified AD for 34 HLA-A, -B, -C and
DRw antigens. Unfortunately the number of controls used
in this study were not specified, and the results for
only 3 HLA antigens were reported. The frequencies of
HLA-B7 (36% v 18%), Cw3 (32% v 20%), and DRw4 (43% v 32%)
were increased over controls.
Walford and Hodge (538) studied 55 patients suffering
from PDAT and SDAT for 36 HLA antigens of the HLA-A, -B,
-C and DR loci, and compared the frequencies obtained
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with an unspecified number of controls. The frequency of
HLA-B7 was found to be significantly increased over the
controls (36.4% v 16.8%, uncorrected P = 0.0001).
Whalley et al (368) examined HLA-A and -B antigen
frequencies in 14 patients with PDAT and 64 healthy
controls, and reported no significant differences
between the patients and controls.
Wilcox, Caspary and Behan (539) studied 10 PDAT
patients who had developed the disease before the age of
60 for HLA-A and -B antigens, but no significant
associations were found. They also studied 8 SDAT
patients, but there is some doubt as to the correct
diagnosis in this group. Apparently there was a previous
history of alcoholism in some, and of a stroke in others.
These studies involved relatively few patients, and
the RR would have to be large for any real HLA
association with AD to show up significantly.
The reported association of AD with HLA-B7 was not
confirmed in the present study. When the RR for HLA-B7
is calculated from each study (Table 25), it is found
to be increased in 4 of the 6 studies, which may
possibly indicate a real association.
As the HLA-C and -D locus antigens were not tested
in this study, the reported association of AD with Cw3
and DR4 cannot be confirmed.
When the RR for HLA-B15 is calculated from each
study (Table 27), it is found to be increased in 3 of the
5 studies. As Walford and Hodge did not include the
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number of controls used in their study, their HLA
findings cannot be combined with data from other centres
for the purposes of statistical analysis. However as there
is no apparent heterogeneity in the results, the HLA-B15
finding of the present study can be combined with the HLA
-B15 findings of the other studies for which the number
of controls are known, using Woolf's formula (521,522).
When all 4 results are combined (Table 26), the
association of HLA-B15 with AD remains statistically
significant (pooled X2 - 10.1538, P - 0.0015), although
the major contribution to the pooled X2 has come from
this study. The weighted estimated mean value of the RR
for HLA-B15 is 1.73. However the failure to find an
increased RR for this antigen in 2 studies indicates that
on present evidence, it cannot be definitely concluded
that HLA-B15 is associated with AD. Further studies
involving larger numbers of patients are clearly
necessary to confirm such an association.
AD may well be a genetically heterogeneous disorder
with polygenic inheritance, and a number of disease
susceptibility genes may predispose to its development.
However if an association of HLA-B15 with PDAT and SDAT
is confirmed, it would suggest that some patients with
the presenile and senile forms of AD share a common
genetic predisposition.
216
Theoretical mechanisms to explain the possible
association of HLA antigens and Alzheimer's disease:
Two main theories have been proposed to explain HLA
and disease associations (446-450,453,463,467,471,540,
541), and both assume that viruses or other pathogenic
agents may be implicated, either directly or indirectly,
in the disease process.
1) The Immune Response Gene Hypothesis:
The most popular theory advanced to explain HLA and
disease association proposes that the association occurs
not as a direct effect of the HLA antigens themselves,
but to the effects of closely linked disease susceptibility
genes. There has been speculation that these disease
susceptibility genes may in fact be immune response (Ir)
genes, which normally control the capacity of the host
to mount an immune response against foreign antigens such
as viruses, but when defective may initiate disease
through a pathological immune response.
There is no direct evidence for the presence of Ir
genes in man, but it is deduced from work in mice and
guinea pigs that they must exist in the major histo¬
compatibility region in man. Ir genes are thought to
map within the HLA region between the B and D loci, and
be in linkage disequilibrium with specific alleles at
the HLA loci (447,448). Therefore in an HLA-associated
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disease, any HLA antigens which are coded for by HLA genes
in linkage disequilibrium with Ir genes, will be increased
in frequency. The closeness of the HLA-B and more recently
recognized -D loci to the proposed Ir genes may explain
why most HLA-associated diseases have their strongest
associations with B and D-locus antigens.
Linkage disequilibrium also occurs between some of
the HLA-A, -B, -C and -D antigens, and the HLA antigens
A2, B15, B40, Cw3 and Dw4 are in linkage disequilibrium
with each other (463,542-544). The relative risks of
developing AD when these antigens are present in this and
other HLA studies of AD are shown in Table 27. The RR
for HLA-A2 is increased in all the studies, although not
significantly. However when the HLA-A2 results are
combined (excluding the Los Angeles results for which the
number of controls are unknown) using Woolf's formula
(Table 28), a statistically significant association with
this antigen is found (pooled X2 = 4.2388, P ■ 0.04).
Similarly the RR for HLA-B40 is also increased in all
the studies, but the association is not statistically
significant when the results are combined using Woolf's
formula (Table 29).
The RR for HLA-Cw3 is also increased in the three
studies which have examined this specificity.
If the associations of these antigens with AD are
real, it might be expected that the primary HLA association
of the disease would be with HLA-Dw4, as the D locus is
thought to be the most closely linked of all the HLA
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loci to the Ir genes. The associations with A2 , B15, B40
and Cw3 would then be secondary. A similar association
for example has been found in juvenile-onset diabetes
which is primarily associated with HLA-Dw4 and secondarily
associated with A2, B15, B40 and Cw3 (542). Also in
multiple sclerosis, the initial associations with HLA-A3
and B7 were fairly weak, but more recent studies have
found a closer association with HLA-Dw2, which is in
linkage disequilibrium with HLA-A3 and B7 (451).
However although the 2 studies which tested AD patients
for the HLA-Dw4 antigen found the expected increase in
frequency, the RR for this antigen is very small.
It is clear that if the associations of HLA-A2, B15,
B40, Cw3 and Dw4 with AD are real, the relative risks for
these antigens are small, and it is impossible to be
sure which shows the strongest HLA association with the
disease. Furthermore if the Ir gene theory is correct,
the association of these HLA antigens with AD would be
secondary to the effects of linkage disequilibrium with a
closely linked Ir gene (or genes) which predisposes to AD.
Evidence in support of Ir genes has come from
experimental work on mice. Murine studies have demonstrat¬
ed that the immune responses to some synthetic and native
antigens, and susceptibility to certain viruses such as
the Gross virus and lymphocytic-choriomeningitis virus,
are partly controlled by genes which lie within the H-2
system (466,453,457,541). In the absence of direct
experimentation, evidence in favour of HLA-associated Ir
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genes in man have been less easy to obtain, and in fact
there is no direct evidence for their presence. One
source of evidence in favour has come from some human
studies of skin test reactions to natural allergens (545)»
Further support for the presence of HLA-associated Ir
genes has come from Buckley and Roseman (546) who found
that antibody levels to common viruses are frequently
HLA-associated within Amish families.
However these and similar studies can be criticized
on several counts. They have been retrospective, and no
consideration has been given to the individual's degree
of previous exposure. Also in some cases, initial
positive findings have not been confirmed.
Associations between autoantibodies and HLA antigens
have also been reported in humans (547).
There is also evidence supporting a direct association
of an HLA-linked Ir gene with a specific immune response,
and severity of disease. Vladutiu and Rose (548) have
shown that the degree of susceptibility to murine auto¬
immune thyroiditis, and thyroid autoantibody response is
related to different alleles of the H-2 locus, and that
the severity of autoimmune thyroid damage is correlated
with the autoantibody response.
Human evidence is less convincing however. Levine,
Stember and Fotino (549) reported that clinical ragweed
hayfever and IgE antibody production specific for antigen
E (the major purified protein antigen from ragweed pollen
extract) was significantly associated with HLA haplotypes
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in successive generations of seven families which they
studied, although other workers have failed to replicate
these results.
The immune response theory is attractive, as many
HLA associated diseases such as juvenile-onset diabetes
and multiple sclerosis are thought to have an immune
aetiology and viral involvement is suspected. There has
been speculation that the destruction of pancreatic
cells in juvenile-onset diabetes results from an HLA-
linked genetically controlled immune response to viruses
(542 )0 This is supported by the findings of Cudworth and
Festenstein (542) that HLA-B8 and B15 positive diabetics
have higher neutralizing antibody titres to Coxsackie
virus (Bl-4 variants) than have diabetics without these
antigens.
Similarly it has been suggested that multiple
sclerosis (MS) may be the consequence of a genetically
controlled immune response which is initially provoked
by a common virus (550,551). MS patients have significant¬
ly higher levels of measles antibody compared with
controls (551), but the findings of Jersild et al (552)
that serum measles antibody titres are significantly
increased in MS patients with HLA A3 and B7, compared to
MS patients with other tissue types, has not been
entirely confirmed (550).
The possible association of HLA-B15 with an immune
response trait to CMV is therefore of interest, and raises
the possibility that Alzheimer's disease could result from
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an abnormal immune response mounted by the host against
CMV infected neurons.
2) Direct effect of the HLA antigens:
This theory proposes that HLA and disease
associations occur not through linkage disequilibrium
with Ir genes, but because of the direct participation of
specific HLA antigens themselves in the disease process.
There are three main ways in which this might be achieved:
a) Molecular mimicry (cross tolerance) hypothesis:
This hypothesis assumes that a pathogenic agent which
directly causes an HLA-associated disease shares common
antigenic determinants with specific HLA antigen(s). An
individual possessing this particular HLA antigen would
then be less likely to recognize the pathogen as foreign
and mount a successful immune response against it. They
would therefore be more susceptible to infection, infection
would be more likely to persist, and disease ensue. It
has been suggested for example that the association of
HLA-B27 and ankylosing spondylitis may be due to cross
reactivity between a klebsiella serotype and a gene product
closely associated with HLA-B27 (553).
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b) Virus receptor hypothesis:
This hypothesis assumes that HLA antigens act as cell
membrane receptors for disease-producing viruses.
Evidence in support of the virus receptor theory has come
from studies which have demonstrated that human influenza
virus-immune cytotoxic T lymphocytes recognize viral
antigens in conjunction with self antigens that are highly
associated with the serologically defined HLA-A and -B
specificities (554).
c) Theory of modified self;
According to this theory, viruses change the immune
characteristics of infected cells, and disease results
from an ensuing autoimmune response. This cellular
modification could be achieved in various ways. For
example new antigenic complexes could result from the
combination of viruses with HLA genes or antigens, or the
genetic apparatus regulating expression of HLA antigens
could become derepressed following viral infection.
The evidence that viruses can alter HLA expression is
far from conclusive, but Pellegrino et al (555) reported
that SV40 virus - transformed human cells expressed an




It is most unlikely that all HLA and disease
associations can be explained by any one theory, and
other mechanisms have been proposed (453,540).
Some HLA-associated diseases may result from defects
in enzyme systems closely linked to the major histocom¬
patibility system. For example, some components of the
complement system are coded for by genes in the HLA
region, and complement deficiencies could perhaps cause
disease by interfering with complement-dependent immune
responses (453,468). Other HLA-associated disorders may
result from the actions of genes at different loci
within the major histocompatibility system which themselves
have no relevance to the functions of this system.
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Centre Canada(536) Seattle and LosAngeles(537) LosAngeles(538) Newcastle and G1asgow(539) Edinburgl(368) Leeds
Nopatients studied 34 25 55 18 14
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Relativeisk
A2 lol 1.5 1.4 1.6 1.5
B15 1.6 0.2 0 1.9 2.5
B40 1.4 1.6 2.1 1.6 1.5
Cw3 2.3 1.9 1.4
Dw4 1.6 1.3
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4) HLA-B15 AND CLINICAL CHARACTERISTICS:
The finding that the male and female patients have
a similarly increased frequency of HLA-B15 is interesting,,
As women have a higher prevalence of AD, it might be
expected that men who develop the disease have a greater
genetic predisposition, and hence show a higher frequency
of genetic markers of disease susceptibility genes such as
HLA-B15 o
This study found no evidence that the possession of
HLA-B15 favours the early development of AD, or influences
its duration. The association of insulin-dependent
diabetes and HLA antigens is strongest in early onset
cases (474), and it is interesting to observe that the
highest proportion of HLA-B15 positive patients found in
this study were those who developed AD between the ages
of 50-54 (55.6%). This finding hints at a possible
association of HLA-B15 with early disease onset, but as
the number of patients included in this particular age







No histological findings were available to confirm
the diagnosis of AD in the secondary cases, and caution is
therefore necessary in the interpretation of the results
of the family studies. However, the occurrence of dementia
in 9.7% of the first degree relatives of patients with AD,
is further evidence that genetic factors are important in
the aetiology of this disorder. The occurrence of cases
of PDAT and SDAT within the same families also suggests
that they share a common genetic predisposition.
The failure to find any significant difference in
the frequency of AD among the relatives of the 10 HLA-B15
positive and 10 HLA-B15 negative patients matched for sex
and age at onset of disease is to be expected if the
association of HLA-B15 and AD is due to linkage disequi¬
librium with a gene predisposing to AD.
The finding of a significantly increased frequency of
AD when the 24 B15 positive patients were compared with the
10 B15 negative patients must be interpreted with great
caution, as far fewer B15 negatives were studied and
statistical sampling error could therefore easily have
arisen.
If susceptibility to disease depends upon the
inheritance of an HLA-linked gene, then it would be expected
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that affected siblings will always be identical for one or
both haplotypeso In the present study only 2 secondary
cases of dementia were alive and available for tissue
typing,, Patient number 62 shared 2 HLA antigens (A2, B15)
in common with an affected younger brother, and patient
number 69 shared identical antigens (Al, 9, B12, 15) with
an affected older sister. However no conclusions can be
drawn about possible linkage of AD susceptibility genes to
HLA genes from this study, as even on the assumption that
there is no linkage, affected sibpairs would have a 25%
chance of being HLA identical, and a 50% chance of sharing
one haplotype. Evidence of HLA linkage in AD must await
larger studies of families with 2 or more affected
relatives still alive and available for tissue typing.
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THE RELATIONSHIP OF





6) THE RELATIONSHIP OF ALZHEIMER 'S DISEASE TO THE
MYELOPROLIFERATIVE DISORDERS A IP DOWN'S SYIPROME;
The increased incidence of myeloproliferative
disorders and Down's syndrome among the relatives of PDAT
cases (102,103) suggests that these conditions may share
a common genetic predisposition, and it is of interest that
2 relatives with a possible history of leukaemia were
found in this study„
If a common genetic factor were linked to the HLA
region, it might be expected that these disorders would
show a common association with the HLA antigens which are
associated with AD.
The earliest reports suggested that Hodgkin's disease
was associated with the compound antigen 4C, which was
later split into HLA-B5, B35, B18 and B15 (556).
Subsequent studies have suggested a weak association with
HLA-A1, B5, B8 and B18 (556).
Acute lymphatic leukaemia is weakly associated with
HLA-A2 (472,473,556), (RR 1.3), and its possession may
also increase survival in the disease (556), perhaps
because patients with this antigen may have a lower
incidence of blood transfusion reactions (557). Harris
et al (558) also found a tendency for HLA-B15 (and A2,
and A3) to increase progressively with survival in
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patients with acute myelogenous leukaemia.
In the only reported HLA study of Down's syndrome,
Segal et al (559) found no significant HLA associations
in 76 patients with this disorder, although the RR for
HLA-B15 was increased (1.6).
These results are interesting in view of the possible
association of HLA-A2 and HLA-B15 with AD, but they do not
allow the conclusion that the myeloproliferative disorders,
Down's syndrome, and AD share a common genetic predis¬






7) CMV ANTIBODY RESULTS
Although AD patients have a higher prevalence of CMV
antibodies than the controls, the difference is not
significant. This study therefore fails to confirm the
findings of Lycke, Norrby and Roos (366) in Sweden,
although the two studies are not strictly comparable.
The Swedish study included some cases of multi-infarct
dementia, and as the patients were older than the
controls, age difference may have been partly responsible
for the higher prevalence of CMV antibodies in the
demented group. A recent Edinburgh study (368) also
found no increased prevalence of CMV antibodies in 14
PDAT patients.
No significant differences are found between HLA-B15
positive and HLA-B15 negative patients in the prevalence
of CMV antibodies. This study therefore fails to confirm
the results of Pereira, James and Stern (560) who found
that a significantly increased number of normal HLA-B15
positive individuals had CMV antibodies compared with
normal HLA-B15 negative people.
Although the geometric mean antibody titre is higher
in the patients than controls, the difference is not
significant. However the mean geometric titre is
significantly higher in the HLA-B15 positives than the
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HLA-B15 negative patients or the controls. Although the
Edinburgh study (368) found that no conventional virus
appeared to be associated with any particular HLA
antigen, it is interesting to note that of the 3 patients
with CMV antibodies in the study, two were HLA-B15
positive.
The finding of an increased CMV antibody titre in the
HLA-B15 positives however raises a theoretical objection
to the hypothesis that the association of B15 with AD
results from linkage disequilibrium with a disease
susceptibility gene. If this theory is correct, no
difference in CMV antibody titre would be expected between
B15 positives and B15 negatives. Such a difference in CMV
antibody titre, if real, would imply genetic heterogeneity.
There are several possible explanations for the
higher mean CMV antibody titres in the HLA-B15 positives
found in this study. It could indicate that HLA-B15 is
an immunological marker for a heightened antibody
response to CMV, which would partly explain the results
of the Swedish study (366) if HLA-B15 is associated with
AD. Alternatively thisheightened antibody response could
also reflect a selective impairment of cell-mediated
immunity to the CMV in HLA-B15 positive patients. An
association between CMV susceptibility and the murine
major histocompatibility complex has also been reported
(561) o
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A further possible explanation is that HLA-B15
phenotypes are high antibody responders to all forms of
antigenic stimulation. However although an association
with HLA-B15 and anti-mitochondrial antibody has been
reported (547), the failure of Pereira, James and Stern
(560) to find any relationship between this antigen and
common virus antibodies, apart from CMV, is against such
a hypothesis.
The possible association of HLA-B15 with an immune
response trait to CMV infection may be an epiphenomenon
and have no relevance to the aetiology of AD, However it
could also indicate that the CMV may have a causative
role in some cases of the disease, either as the direct
result of persistent infection, or through the initiation
of an aberrant immune response within the brain. The
failure to find elevated serum CMV antibodies in the HLA-
B15 negative patients does not necessarily preclude such
a possibility, for although perhaps initiating the
disease, the CMV may no longer be present when dementia
becomes apparent, or may be present in a defective form.
In the following discussion the various mechanisms by
which persistent CMV infection could be of aetiological
importance in AD will be considered.
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Possible mechanisms by which Alzheimer's disease could
result from persistent CMV infection;
There are two main ways in which persistent CMV
infection could play an aetiological role in AD.
1) Direct effect of CMV on neurons:
a) Direct cytopathic effect:
Reactivation and replication of latent CMV within the
brain as the result of an age-related decline in cell-
mediated immunity, could destroy infected neurons by a
cytopathic effect, and a resultant acute inflammatory
response against the neuronal breakdown products.
However, although much of the tissue damage in congenital
CMV infection and herpesvirus encephalitides is thought to
be produced in this manner, it is very unlikely that the
neuropathological features of Alzheimer's disease could
result from such a process. The failure to grow
conventional CMV in cell cultures from AD brain specimens
is also against the concept of a direct involvement of an
acute CMV infection in the pathogenesis of this disorder.
b) Interference with neuronal metabolism;
Gajdusek (562) has speculated that if metabolic or
biochemical factors of cell ageing with enzyme exhaustion
underlie the formation of senile plaques and neurofibril¬
lary tangles in the ageing brain, similar but premature
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cellular metabolic changes might be induced by slow,
latent or modified defective viruses.
It is therefore possible that latent or modified CMV
could persist in an integrated state within the neurons,
despite high levels of CMV antibody which cannot penetrate
cells (563), with adverse effects on neuronal metabolism.
2) Effect of CMV on the immune system:
The evidence which suggests that the pathogenesis of
AD is mediated through immune mechanisms has already been
considered. There are a variety of ways in which the CMV
could initiate an abnormal immune response which could
result in AD:
a ) Immune complex disease:
Immune complex disease results when antigen and host
antibody aggregates are formed and deposited into tissues
over a long period of time. Immune complexes (IC) can be
formed in chronic viral infections (564-566) in which
viral antigens and host antibody are being constantly
produced.
Infection of newborn mice with lymphocytic
choriomeningitis (LCM) virus for example, results in a
persistent infection with the formation of immune
complexes which are deposited in kidneys, blood vessels
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and the choroid plexus of the CNS, but disease is not
manifested until 7-10 months later (564,567,568). The
incubation period of congenital and neonatal LCM infection
is more than half the normal expected life span of mice,
and the disease has been likened to premature senesence (568).
Transient immune complex formation has been reported
in acute CMV infections, which disappear following clinical
recovery (569-571).
It is unknown whether a chronic CMV infection
resulting from the reactivation of the virus from a latent
state could induce prolonged immune complex formation.
However immune complexes have been detected in the renal
glomeruli of mice with chronic CMV infection (572), and
have also been found in patients with clinical and
subclinical congenital CMV infections during the first
year of life (573).
The pathology of Aleutian disease of mink, which is
caused by a slow virus, is thought to be mediated by immune
complexes (574), but at present there is little evidence
to suggest that Alzheimer's disease is similarly mediated.
However Wisniewski and Terry (575) have speculated that in
Alzheimer's disease, changes in the permeability of the
blood-brain barrier could result in toxic antigen-antibody
complexes leaking out of the blood stream to cause neuritic
degeneration and senile plaque formation.
b) Autoimmunity;
Transient immunological abnormalities and autoimmune
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phenomena, including autoimmune haemolytic anaemia,
rheumatoid factor, antinuclear antibodies, cold agglutin¬
ins, cryoglobulins and positive Coomb's tests, have been
observed in acute congenital human (411,412,569-571,576)
and chronic murine (572) CMV infections. It is unclear
whether these autoantibodies have any primary pathogenic
significance or are merely secondary to tissue damage
produced by CMV infection. However their presence raises
the possibility that CMV infection could play a role in
the pathogenesis of Alzheimer's disease by the initiation
of an antibody or cell-mediated autoimmune reaction
against virus-infected neurons. This could be achieved
in a variety of ways:
1) Release of sequestered antigens:
Replication of CMV with subsequent neuronal
destruction, could result in the release of intracellular
components such as DNA and mitochondria, and conceivably
an autoimmune response could be provoked against these
newly exposed antigens. The reported association of
HLA-B15 and enhanced autoantibody response to mitochond¬
ria (547) is interesting in this context, and raises the
possibility that CMV infection could accelerate this
proce ss«
2) Virus-induced cell membrane alterations:
Herpesviruses can induce new virus-specific antigens
on the surfaces of infected cells (566,577). Human
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fibroblasts have also been shown to develop a new HLA
antigen specificity after transformation with the virus
SV40 (555).
3) Cross-reactivity between viral and host antigens:
CMV infection could provoke an autoimmune response if
the virus and the host shared common antigenic
determinants. Viruses may incorporate host cell antigens
into their own cell walls as they enter or leave a cell,
and also during viral assembly. In this situation an
antiviral immune response could also be directed against
host cells as well as the virus.
4) Infection of lymphocytes and macrophages:
Human CMV can infect and replicate in lymphocytes and
macrophages, which could lead to a genetic alteration and
function of these cells, and the initiation of an auto¬
immune response. For example, the loss of suppressor T
cell control over B cells, or stimulation of autoantibody-
producing B cells following CMV infection, could trigger
such a process.
c) Immune suppression;
If the decline in immunity with increasing age
predisposes to the development of Alzheimer's disease,
CMV could be an important aetiological factor because of
their immunosuppressive potential.
In mice, CMV infection causes depression of primary
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and secondary humoral immune responses (578), and cell-
mediated immunity to other antigens (579), and a
significant decrease in the percentage of peripheral
blood T cells has been reported in children congenitally
infected with CMV (392,580). The immunosuppressive effect
of murine CMV may be mediated by interaction of the virus
with individual subpopulations of lymphocytes such as
suppressor T cells, or macrophages (578), and similar
mechanisms may be operating in human CMV infections.
Macrophages are often found within senile plaques, and
Scheinberg and Cathcart (213) have postulated that
macrophage activation represents the initial step in the
genesis of amyloid formation.
Immunosuppression can accelerate amyloid formation in
experimental animals, and the report of Sim and Smith (581)
that the clinical state of two patients with Alzheimer's
disease actually deteriorated following treatment with
cortisone and ACTH, is of some interest in this context.
d) Suppression of interferon;
Interferon is an antiviral glycoprotein produced by
cells already infected with virus, which prevents viral
replication in uninfected cells by inhibiting viral
transcription and/or translation.
Murine CMV has been shown to inhibit interferon
responses, and to have a synergistic effect on Newcastle
disease virus in mice (582). It is therefore possible
that human CMV could play a role in the development of
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AD through their ability to suppress interferon responses,
or through synergistic interaction with other viruses









8) CREUTZFELDT-JAKOB DISEASE IN AN HLA-B15
POSITIVE 15 YEAR OLD GIRL:
The very young age at onset of CJD in the patient
D.H., and her high antibody titre to BK virus are
worthy of note. However as Dr. A. Gay will be reporting
this case in detail in the future, the writer's comments
will be confined to the HLA findings, and the possible
relationship of CJD to AD.
There are several features of CJD and AD which
suggests a link between these two disorders. Their
clinical findings can be very similar (583,584), and the
stellate amyloid plaques which are common in AD are also
found in about 10% of brains with CJD (312,328,585). The
pathological changes of both CJD and AD have also been
found in the same brain (329). The reports of the
occurrence of AD and CJD in different members of the same
family (69) is further support for an association between
these two disorders.
Only about 6% of Africans are HLA-B15 positive (455),
so that the possession of this antigen by the patient D.H.
raises the possibility that CJD and AD share a common
genetic predisposition, and perhaps even a common
infectious aetiology.
A study (337) of HLA antigens in 25 members of a
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Finnish family in which CJD was diagnosed in 8 cases,
revealed no obvious linkage of the disease with a single
haplotype, but at least 7 out of the 8 patients
apparently showed the HLA antigens A28 and B8. Further
studies of the sporadic cases of CJD are indicated to
see if the disease is associated with any particular HLA
antigen. However as the disorder is rare, it would be
difficult to accumulate sufficient numbers of patients at
any one centre.
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9) PDAT IN ONE OF MONOZYGOTIC TWIN SISTERS;
The occurrence of PDAT in only one of identical twins
argues strongly that non-genetic factors are aetiologic-
ally important in some cases of AD. Three other cases of
PDAT occurring in monozygotic twins have been reported:
Davidson and Robertson (586) described a woman with
acne rosacea who started to dement at the age of 50, and
who died aged 69, the post-mortem confirming the diagnosis
of PDAT. The patient and her twin sister, who was
unaffected, were considered to be identical, although no
laboratory investigations were done to prove uniovularity.
The affected twin had suffered from severe influenza with
delirium and fever at the age of 38 during the 1918-19
epidemic.
Hunter, Dayan and Wilson (587) reported a second pair
of female monozygotic twins with laboratory proof of
uniovularity, who were apparently discordant for PDAT.
Their patient died aged 64 after a dementing illness
lasting 15 years, and at post-mortem the brain showed the
typical features of AD. Her twin sister was unaffected.
Sharman et al (588) described PDAT in identical twin
brothers. The disease was confirmed histologically in
both, but no special genetic studies were carried out on
the twins to prove monozygosity„ Both brothers developed
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the disease insidiously at the age of 34, and died 4
years later. Their mother had also developed a dementing
illness at the age of 37, and died 5 years later. At
post-mortem, her brain was found to be atrophied, but no
histological examination was performed.
The affected twins in these reported cases have some
features in common with the present case. In 3 of the 4
cases, twitching movements of the limbs were observed
during the disease. Similar muscular twitchings in AD
have been described by Jacob (589). In addition, all the
discordant pairs were women, and their lengths of illness
were unusually long.
The discordance for PDAT observed in 3 sets of
identical twins suggests that environmental factors were
operating in these cases, and clearly points to the need
for further research in this area. However discordance
does not prove that genetic factors are unimportant in
PDAT, as they may act by increasing susceptibility to the






The following main conclusions are drawn from the
observations of this study:
1) ABO blood groups do not appear to influence
susceptibility to AD.
2) Persons who are rhesus negative may have a
slightly increased risk of developing SDAT compared with
rhesus positives. The failure to find a similar
association in the PDAT group of patients may be the
result of a statistical sampling error due to the small
number of patients studied, but may also indicate that AD
is a genetically heterogeneous disorder.
3) Persons who are HLA-B15 positive may be more
predisposed to PDAT and SDAT than those without this
tissue type.
4) The possible association of HLA-A2, B15, B40,
Cw3 and Dw4 with AD may be secondary to the effects of
linkage disequilibrium with a closely linked immune
response gene predisposing to the disease.
5) The possible association of HLA-B15 with FDAT
and SDAT supports the hypothesis that some patients with
the presenile and senile forms of AD share a common
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genetic predisposition®
6) The occurrence of cases of PDAT and SDAT within
the same families is evidence that genetic factors are
implicated in these disorders, and is further support for
a common genetic predisposition.
7) The possession of HLA-B15 does not appear to
favour the early development of AD or influence its
duration.
8) AD patients who are HLA-B15 positive do not
appear to have a stronger family history of AD than
patients without this tissue type.
9) The occurrence of PDAT in only one of identical
twins suggests that environmental factors are aetiologic-
ally important in some cases of the disease.
10) The finding that AD patients have similar CMV
antibody titres to non-demented controls of a similar
age, and the failure to detect conventional CMV
activity in cell cultures, argues against a direct
causal role for these viruses in most cases of AD.
11) The finding that HLA-B15 positive AD patients
have higher mean antibody titres to CMV than AD patients
with other tissue types, suggests that HLA-B15 is an
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immunological marker for a heightened antibody response to
these viruses, although may also reflect a defect in
cellular immunity. Further studies of cellular and
humoral immunity to CMV in AD patients are warranted.
12) The possible association of HLA-B15 with an
immune response trait to CMV raises the possibility that
these viruses may play an indirect role in the
aetiology of AD in the HLA-B15 positive patients, perhaps
through the initiation of an abnormal immune response





Details of the tissue-typing technique used at the Leeds
Regional Blood Transfusion Centre
1) Preparation of lymphocyte suspension:
(a) Approximately 3 ml quantities of heparinised
blood is carefully layered onto equal amounts of
Ficoll - Triosil mixture in labelled Rh tubes using
a clean pasteur pipette.
Ficoll - Triosil mixture: 10 parts of 34% Triosil +
26 parts of 9% Ficoll mixed, SG adjusted to 1.076.
(b) Spin tubes at 2,000 rpm for 20 minutes (MSE)
and then carefully remove the lymphocyte/platelet
layer, with a clean pasteur pipette into labelled
plastic centrifuge tubes. Fill tubes with Hank's
balanced salt solution (HBSS).
(c) Wash lymphocytes 3 times in HBSS at 1,000 rpm
for 5 minutes (MSE) discarding the supernatant and
gently resuspending the lymphocyte button.
Finally resuspend the lymphocyte button in HBSS to
give approximately 2 x 106/ml concentration.
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APPENDIX 1 - continued
2) Tissue-typing procedure:
Both National and Leeds typing plates are loaded with
1 pi of serum.
(a) Add 1 pi of lymphocyte suspension at 2 x 10^/ml
to each sera well, wiping the pipette needle carefully
between each well and ensure that all sera and cells
are mixed together. Incubate the typing plate at
room temperature for 30 minutes.
(b) Add 5 pi of rabbit complement to each well,
carefully wiping the pipette needle between each
well, and incubate at room temperature for a further
60 minutes.
(c) Add 2 pi of 5% Eosin (4°C) to each well, leave
at room temperature for 10 minutes, add 2 pi of
formaldehyde solution (4°C) and read using inverted,
phase contrast microscopy. The percentage of dead
cells should be assessed as accurately as possible
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